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Summary
Malignant mesothelioma (MM) is an aggressive cancer, the consequence of which is
neoplastic transformation of mesothelial cells and is strongly associated with
previous asbestos exposure. The disease is associated with poor patient survival due
to difficulties in diagnosis and treatment options currently available. Therefore, it is
essential to identify novel molecular targets that can be used to develop new
treatment opportunities. Hedgehog (Hh) and transforming growth factor-beta (TGFβ) signalling pathways are involved in numerous overlapping developmental
processes as well as tissue repair and tumorigenesis. Recently, TGF-β has been
shown to induce the expression of Hh signalling effector molecules, the Gli
transcriptional factors in various cancer cell types. Our laboratory has been interested
in assessing the interaction between the TGF-β and Hh signalling pathways and how
this interaction may contribute to tumour growth and metastasis in MM.
This study will test the hypothesis that TGF-β induces Gli1 and Gli2 expression in
MM cells through activation of the SMAD signalling pathway. To test the
hypothesis, this study addresses three aims. Aim 1, to examine the effect of TGF-β
on Gli expression. Aim 2, to determine if TGF-β-induced Gli mRNA is independent
of the Hh signalling pathway and to examine the effects of blocking TGF-β on Gli
mRNA levels and aim 3, to determine the signalling pathway through which TGF-β
regulates Gli expression.
MM and control mesothelial cells all expressed variable amounts of basal TGF-β1
and TGF-β2 mRNA with most MM cells expressing quantitatively higher TGF-β1 but
lower TGF-β2 mRNA than controls. Basal levels of Gli1 and Gli2 mRNA were
variable across the cell lines but Gli2 was upregulated in all cells upon TGF-β2
stimulation. TGF-β1 had no effect on Gli1 or Gli2 mRNA levels and TGF-β2 had no
effect on Gli1 mRNA levels. These findings are different to previous studies in
different cancers where TGF-β1 has been shown to upregulate early expression of
Gli2 mRNA and subsequent upregulation of Gli1. This is the first time the effect of
TGF-β2 has been examined in any cell line.
The mechanism of TGF-β2-mediated Gli2 mRNA expression was also examined
using pharmacological inhibitors to the type I TGF-β receptor ALK5, and siRNA

iii

against key mediators of the TGF-β SMAD signalling pathway, SMAD2 and
SMAD3. Inhibition of ALK5 and SMAD2 and SMAD3 inhibited TGF-β2-induced
Gli2 expression, confirming that TGF-β2-mediated Gli2 expression is SMAD2/3
dependent. Further studies are required to determine if TGF-β2-mediated Gli2
expression is independent of the classical Hh signalling Patched/Smoothened
(Ptch/SMO) receptor complex.
In conclusion, TGF-β2 was identified as a potent transcriptional inducer of Gli2
transcription factor. These findings may be valuable in providing new therapeutic
opportunities to treat MM using targeted TGF-β and Gli therapies. Further studies
are now required to examine the functional importance of TGF-β2-mediated Gli2
expression in MM cell function and tumour growth.
In conclusion, TGF-β2 was identified as a potent transcriptional inducer of Gli2
transcriptional factor. These findings may be valuable in providing new therapeutic
opportunities to treat MM using targeted TGF-β2 and Gli2 therapies. However, to
make a definitive conclusion about this aspect, further studies need to be completed
examining their functional importance in MM tumour growth.
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Chapter 1
Introduction &
literature review

1

1.1 Introduction
The mesothelium comprises a monolayer of mesothelial cells extending over the
surface of the serosal cavities and organs (Whitaker, Papadimitriou & Walters,
1982), with a main functional role of providing frictionless free movement between
these tissues and organs, as well as protecting from infection and injury (Yung &
Chan, 2007). Malignant transformation of mesothelial cells is closely linked to
asbestos exposure (Spugnini, Bosari, Citro, Lorenzon, Cognetti, Baldi, 2006), and
leads to the development of malignant mesothelioma (MM) (Mutsaers, 2004), MM
an aggressive cancer with a poor prognosis. It has been well established that MM is
largely unresponsive to traditional cancer treatments such as chemotherapy or
radiation (Spugnini et al., 2006) and therefore novel therapeutic approaches are
required.

In recent years the role of developmental signalling pathways has become an
important focus of research in certain cancers and increasing evidence implicates the
reactivation and aberrant expression of these pathways as critical to their
pathogenesis. Two of these pathways are the hedgehog (Hh) and transforming
growth factor β (TGF-β) signalling pathways. Both pathways have been individually
studied in various cancers, however the molecular and cellular mechanisms behind
their regulation of tumour growth are still unclear. Recent evidence has demonstrated
a link between these pathways, and how they may work together to promote tumour
growth and metastases in various cancers including gastric, breast and pancreatic
adenocarcinomas. This current study will examine the interaction between the Hh
and TGF-β signalling pathways in MM. The emerging picture of Glioma-associated
oncogene homologue (Gli) transcription factors as an integrative platform of
signalling pathways could have important implications in understanding tumour
growth and development. Thus, examining how these pathways interact will expand
the current understanding of the growth and development of this disease which may
open new avenues for therapeutic approaches against MM progression.

2

1. 2 The mesothelium
1.2.1 Structure
The mesothelium is derived from mesodermal tissue and extends over the entire
surface of the pleura, pericardial and peritoneal surfaces (Mutsaers, 2004; Whitaker
et al., 1982) and lines the sac that surrounds the testes (Mutsaers, 2004). The cells are
25µm in diameter and predominantly flattened, squamous like with surface
microvilli resting on a thin basement membrane supported by connective tissue
stroma and are present in greater numbers on the visceral (outer) surfaces compared
to the parietal (inner) surfaces, Figure 1.1 & 1.2 (Whitaker et al., 1982).

Figure 1.1: A double layered mesothelium (arrows) on the visceral serosa of the lung
of a 4 ½ week old human embryo (magnification x 500) (reproduced from Whitaker
et al., 1982).

Despite the fact that the mesothelium is mainly composed of flattened cells, cuboidal
cells can also be found in the milky spots of the omentum, within the septal folds of
the mediastinal pleura and on the peritoneal side of the diaphragm overlying the
lymphatic lacunae (Whitaker et al., 1982).
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Figure 1.2: Electron micrograph of luminal aspect of mesothelium covered with a
carpet of microvilli. Bar 3.2 µM (reproduced from Mutsaers, 2004).

1.2.2 Function
Although the structural organisation of the mesothelium indicates that it is a simple
tissue, its functions are quite complex. The major functional roles of the mesothelium
is to serve as a protective barrier against abrasion and infection, and to provide a
frictionless interface to facilitate the free movement of opposing tissues and organs
(Mutsaers, 2004). Tight junctions bind the mesothelial cells together. Secreted
surface glycosaminoglycans, proteoglycans and surfactant lubricants secreted by the
mesothelial cells, provide a non-adhesive glycocalyx and fluid lining that protects the
serosal surface from abrasive damage and infection (Mutsaers, 2004; Whitaker et al.,
1982).

Compelling evidence also highlights the importance of the mesothelium immune
surveillance, where the mesothelium can initiate a specific immune response against
an invading agent (Yung & Chan, 2007). The mesothelium can also transport fluid
and solutes across the serosal membrane through pinocytic vesicles, intracellular
junction and stromata (supporting framework of a cell), which allows rapid removal
of fluid and cells from the serosal cavities to the underlying lymphatic system (Yung
& Chan, 2007). In addition to these function, the mesothelial cells participate in
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initiating and resolving serosal inflammation and repair, preventing adhesion
formation through lysis of fibrin deposits and providing protection (a process of the
immune system whereby cells capture antigen and enable their recognition by Tcells) against invading microorganisms (Mutsaers, 2004). The mesothelium also
performs other functions that are essential for serosal homeostasis such as antigen
presentation, synthesis of inflammatory growth factors and mediators (Mutsaers,
2004; Yung & Chan, 2007) and an active role in fibrin deposition and clearance
(Yung & Chan, 2007).

1.3 Malignant Mesothelioma
MM is classified by its histological appearance, and according to the World Health
Organization (WHO), this classification is in four main types; epithelioid,
sarcomatoid, desmoplastic and biphasic (Izzi, Masuelli, Ttesoldi, Foti, Modesti &
Bei, 2012). Patients with epithelioid MM often survive longer, while sarcomatoid
MM is associated with poor prognosis (Sekido, 2010). The most important risk factor
associated with MM is exposures to silicate asbestos fibres, but simian virus 40
(SV40) and genetic predisposition have also been linked to the disease (Husain et al.,
2009). MM is resistant to chemotherapy and radiation therapy; in addition, current
therapeutic approaches have so far proven to be ineffective to halt disease
progression (Spugnini et al., 2006).
Malignant pleural mesothelioma (MPM) is the most common form of MM, followed
by peritoneal malignant mesothelioma (PMM), then pericardial MM (Sekido, 2010).
MPM patients commonly present with a pleural effusion associated with chest pain
and dyspnoea (Boutin, Schlesser, Frenay, & Astoul, 1998). PMM is often found as a
large tumour mass on the omentum, or as a diffuse tumour of the intestinal serosa
(Moore, Parker & Wiggins, 2008). PMM presents with nonspecific symptoms
including nausea, vomiting, constipation, diarrhoea and loss of appetite, with small
bowel obstruction a late feature (Moore et al., 2008; Spugnini et al., 2006).
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1.3.1 Epidemiology
MM before 1950 was so rare that pathologists questioned its existence (Garlepp &
Leong, 1995). Wagner and colleagues established the link between asbestos and MM
in 1960 based on the epidemiological data from South Africa (Wagner, Sleggs &
Marchand, 1960). In Australia, the first reported case of MM was in a Wittenoom
worker in 1962 and reports from other Australian states followed thereafter
(McNulty, 1962). Although the use of asbestos was widely abandoned around 1980’s
in the western world, the long latency period between the exposure to asbestos and
the onset of MM, which can range from 15 to 60 years, meant that the mortality rates
from MM have continued to rise (Moore et al., 2008). The occurrence of MM is
higher in males (70-80%) than in females, and the diagnosis of the disease is usually
made 20 to 40 years following exposures to asbestos (Moore et al., 2008). Based on
this, the worldwide incidence of MM is predicted to peak in the next 20 years (Rudd,
2010). However, in non-western and developing countries where asbestos was used
later then in western countries in some cases is still being used, there is a predicted
corresponding delay in the anticipated peak incidences of MM (Leigh, Davidson,
Hendrie, & Berry, 2002).

1.3.2 Aetiology
Asbestos refers to a group of naturally occurring hydrated mineral silicate fibres
(Moore et al., 2008). The two main forms are serpentine asbestos; represented by
chrysotile (white asbestos), and amphibole asbestos; which includes crocidolite (blue
asbestos), amosite (brown asbestos), actinolite, tremolite and antheophyllite, (Rudd,
2010). Crocidolite, comprising of long thin fibres, are considered to be the most
oncogenic type of asbestos fibre because they are able to penetrate the lungs resulting
in repeated damage and tissue repair as well as local inflammation (Sekido, 2008).
The action of asbestos fibres in the pathogenesis of MM is still unclear, but the
toxicity of most asbestos is dependent on the chemical and physical properties of the
fibres and the time from the initial exposure (Kamp, 2009). Other factors such as
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genetic predisposition are also likely to impact on the development of MM (Sekido,
2008). For example, studies examining Turkish families from three different villages,
showed a cluster of MM cases with an autosomal dominant pattern, suggesting a
possible genetic cause for the disease (Dogan, Baris, & Dogan, 2006).
SV40 is a DNA virus found in both monkeys and humans which can induce tumour
development by blocking tumour suppressor genes (Rudd, 2010). SV40 virus has
been proposed as an etiological agent for MM, but although its role in MM
pathogenesis remains controversial (Murthy & Testa, 1999). It is thought to have a
strong co-carcinogenic effect when associated with asbestos (Murthy & Testa, 1999).

1.3.3 Pathogenesis
MM induced by asbestos is thought to occur in four main processes. Firstly, asbestos
has the ability to penetrate deeply into the serosal cavities and is thought to
contribute to mechanical injury to the mesothelial cells which than initiates repeated
cycles of damage, repair and inflammation (Rudd, 2010). Secondly, asbestos fibres
may pierce the cells and disrupt the mitotic spindle of cells, affecting mitosis which
may result in chromosomal damage such as aneuploidy (Sekido, 2010). Loss of
chromosomes in MM, such as chromosome 22, causes aberrant or no expression of
the Neurofibromatosis type 2 (NF2) tumour suppressor gene (Murthy & Testa,
1999). It has been noted that NF2 gene is inactivated by homozygous deletion,
missense or nonsense mutations in 40-50% of MM cases (Sekido et al., 1995). A
recent study has demonstrated that somatic mutations in the BAP1 (BRCA 1associated protein 1) gene caused by the loss of an allele at 3p21 region, was found
in 23% of MM patients (Rascoe, Jupiter, Cao, Littlejohn, & Smythe, 2012). Thirdly,
asbestos can cause DNA strand breaks mediated by iron catalysed free radicals.
Asbestos causes the release of reactive oxygen species (ROS) and nitrogen species
(NOS), which can directly induce genotoxicity including base deletions,
substitutions, insertion, sister chromatid exchange, rearrangements and chromosomal
aberrations (Kamp & Weitzman, 2009). These may then lead to mutations in the
mammalian cells, and subsequently the cell transforms and is able to resist apoptosis
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and undergo transformation (Kamp & Weitzman, 2009). Recently, Shukla et al,
(2009) proposed that asbestos causes mesothelial cell death, primarily through
programmed necrosis, involving H₂O₂ secretion, ATP depletion and high-mobility
group box 1 protein (HMGB1) release, thereby promoting an inflammatory response.
Fourthly, asbestos fibres induce the persistent activation of signalling pathways such
as ERK1/2 involved in cell proliferation, protein metabolism and signal transduction,
which are significantly altered in mesothelial cells after asbestos exposure (Kamp &
Weitzman, 2009). Recent studies demonstrated critical roles for tumour necrosis
factor-alpha (TNF-α) and nuclear factor-kB (NF-kB) in MM pathogenesis (Yang et
al., 2006). Following asbestos exposure, macrophages accumulate in the pleura and
lungs that secrete TNF-α, which binds to its receptor TNF-R1 and activates the NFkB pathway. This activation allows mesothelial cells with asbestos induced DNA
damage to divide rather than die, eventually developing MM (Yang et al., 2006). In
addition to TNF-α, other cytokines and growth factors have been implicated in
asbestos carcinogenesis, and their role in MM pathogenesis is being investigated
(Sekido, 2010). Examples include: transforming growth factor-β (TGF-β),
interleukin (IL) 6 and 8, which may have a role in stimulating tumour growth, and
platelet derived growth factor (PDGF), which might act as regulatory factor in MM
cell proliferation (Shukla et al., 2009).

1.3.4 Current Treatments
MM has a poor prognosis with an inevitable fatal course and very few long term
survivors. MM cells have shown particular resistance to current available
chemotherapy treatments with a median survival of 8 to 12 months and less than
20% response rate. Single line therapy (recommended initial treatment for MM) has
not been successful. To date, the combination of pemetrexed and cisplatin has
yielded the best results, with 12.1 months survival rate, and 41% response rate in a
phase III clinical trial (Vandermeers et al., 2009). However, these agents interfere
with the cell division process and in turn activates apoptosis (Spugnini et al., 2006),
and the major concern with this treatment is rapid relapse, acute toxicity and shorter
response duration. Radiation therapy has also been ineffective in prolonging patient
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survival. However, some studies have shown gross disease regression after radiation
therapy (Gregoire, 2010). In some studies, surgery has had beneficial responses with
pleurectomy and extrapleural pneumonectomy (EPP). The most effective
pleurectomy involves removal of the parietal (lines the inner pleural cavity and
covers the diaphragm) and/or visceral (a thin serosal membrane around the inner
walls of the lungs) pleura, leaving the underlying lung. EPP involves removal of the
entire pleural envelop and its content as well as the affected lung, diaphragm and a
portion of the pericardium. However, both pleurectomy and EPP have not
consistently been shown to significantly prolong MM patient survival (Sugarbaker,
Heher & Lee, 1991).

In general, therapeutic options including surgery, radiation, chemotherapy,
immunotherapy and gene therapy, have had limited success to date. Therefore,
current research is focussing on targeted molecular therapeutic approaches. Gene
mutations and accumulation of these mutations, together with aberrant activation of
growth regulatory pathways, has been linked to many cancers including MM. Hence,
a better understanding of the underlying mechanisms regulating MM growth will
help to identify molecular targets that can be used for diagnosis, prognosis and
therapies. This is critical for many Australians with past asbestos exposure who have
an increased future risk of developing MM.

1.4 Role of signalling pathways in MM
There has been a lot of interest in recent years in the role of cell signalling pathways
in cancer. In particular the reactivation of classical developmental signalling
pathways’, and their role in the early event of cell transformation. Reactivation of
these pathways leads to various processes such as cell cycle regulation, apoptosis and
angiogenesis. There is also increasing evidence of aberrant activation of these
pathways. It is evident that distinct epigenetic and genetic events characterize the
interplay between the molecules involved in these pathways. Involvement of the
cytokine TNF-α and molecular pathway NF-kB in MM have been briefly described
earlier. Similarly, studies have shown the involvement of other growth factors and
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molecular pathways linked to MM, among these is TGF-β together with Ras, Hippo
and Wnt signalling pathways (Zucali, Ceresoli, De Vincenzo, Simonelli, Lorenzi, &
Gianoncelli, 2011). Another pathway, the Hedgehog pathway, has clearly been
associated with tumorigenesis, with mutations in this pathway leading to
hyperactivation of the pathway identified in a variety of cancers. However, its
reactivation and aberrant activation in the growth and development in MM remains
to be determined. In addition, recent evidence has shown crosstalk between the Hh
and TGF-β signalling pathways. Several studies have shown that TGF-β can
upregulate the important Hh pathway effector molecule Glioma-associated oncogene
homologue (Gli) (Zucali et al., 2011). As we know that TGF-β is an important
molecule for MM growth, studies into the interaction of these pathways in MM may
identify novel therapeutic approaches to treat this disease.

1.5 The Hedgehog signalling pathway in development
Complex body plans requires the involvement of cell-cell signalling pathways. The
discovery of the Hh gene was made through a genetic screen of mutations that
disrupt the Drosophila larval body plan (Nusslein-Volhard & Wieschaus, 1980). The
gene mutation resulted in disruption to the dorsal-ventral body plan of the larva
leading to an abnormal distribution of hair-like projections on its ventral surface,
called denticles. These hairs are distributed at regular intervals forming bands across
the ventral surface and they appear along the entire length of the larva. The gene
mutation identified by Nusslein, Volhard and Wieschaus lead to ectopic production
of denticles on the ventral surface leading to the physical appearance of the larva that
resembled that of a hedgehog. Thus, the gene and subsequent signalling pathway was
given the name Hedgehog signalling pathway (Ingham & McMahon, 2001). Hh is a
secreted protein that acts as an intercellular signalling protein. Hh proteins have been
identified in a range of vertebrate species that function as key mediators of many
fundamental processes. There are three mammalian Hh genes activating the same
canonical signalling pathway, and these are sonic hedgehog (Shh), dessert hedgehog
(Dhh) and indian hedgehog (Ihh) (Ingham & McMahon, 2001). Shh is the most
extensively studied ligand that has not only been associated with developmental

10

processes but also more recently has been implicated in some disease processes in
man (Watkins, Berman, Burkholder, Wang, Beachy & Baylin, 2003).

1.5.1 Biological function
The Hh family of intercellular signalling proteins have been recognised as key
mediators of several fundamental processes in embryonic development (Ingham &
McMahon, 2001). The activities of these proteins are critical to the growth,
morphogenesis and patterning of many different regions within the body plans of
insects and vertebrates, and in most invertebrates (Ingham & McMahon, 2001). In
embryonic development of a Drosophila, Hh is a central patterning signal in the
wing, eye discs and leg (Herberlein, Singh, Luk, & Donohoe, 1995), together with
regulating other processes such as germ cell migration, development of gonad,
abdomen, tracheal system and optic lamina (Glazer & Shilo, 2001). Hh genes have
also been identified in other species such as sea urchin and leech (Chang, Lopez,
Von Kessler, Chiang, Simandl, Zhao, 1994). In vertebrate embryos, Shh expression
has been observed in three key signalling centres, the floor plate, notochord and the
zone of polarizing activity (ZPA), during limb bud development (Ingham &
McMahon, 2001). The importance of notochord and floor plate is in the
ventralization of the developing neural tube, whereas the ZPA plays a role in
regulating anterior polarity (Ingham & McMahon, 2001). This suggests that the
discovery of Shh provided an insight into neural tube and limbs formations thus,
suggesting a molecular link in the development of distinct vertebrate body plans. In
general, Shh signals can regulate cell proliferation, cell fate specification, and cell
survival by inducing the expression of a range of target genes. For instance, Shh in
blood cells plays a role in stem cell proliferation, thrombocyte differentiation and
activation of haematopoiesis (Dyer, Farrington, Mohn, Munday & Baron, 2001). In
the heart, Shh controls cardiac morphogenesis (Zhang, Santos & McMahon, 2001).
In the limbs, Shh regulates anterior-posterior patterning of the skeleton (Dyer et al.,
2001). In the lungs, Shh controls branching epithelium together with proliferation
and survival of mesenchyme cells (Pepicelli, Lewis & McMahon, 1998). Shh also
controls growth and morphogenesis in prostate and tooth (Ingham & McMahon,
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2001). Crucial developmental functions of Hh signalling in embryonic development
is illustrated by defects in this pathway, which results in several foetal abnormalities
in the brain, facial and midline (Belloni, Muenke, Roessler, Traverso, Siegel-Bartelt,
& Frumkin, 1996). These defects are defined in holoprosencephaly, microencephaly
and cyclopia (Gupta, Takebe & LoRusso, 2010). Holoprosencephaly is a disorder
involving the development of midline and forebrain, in which the ventral cell types
are lost, and in humans is caused by mutations that lead to Shh activity (Belloni et
al., 1996).

In adults, the Hh pathway remains active, and is particularly involved in regulating
tissue homeostasis and in continuous renewal and repair processes of adult tissues
(Ingham & McMahon, 2001). The Hh pathway also plays a critical role in adult stem
cell maintenance (Hooper & Scott, 2005). Most of the renewing tissues, such as skin
and bone marrow, are maintained by stem cells that demonstrate the ability to both
give rise to mature cell types of that specific tissue and to generate additional stem
cells. The Hh signalling regulates stem cell activity through stimulating proliferation
and self-renewal of stem cells in various tissues ((Reya, Morrison, Clarke &
Weissman, 2001).

1.5.2 Signal Transduction
Hh signal transduction is induced after the initial modification of the Hh ligands. The
Hh proteins are synthesised as 45kD precursor proteins that undergo intramolecular
cleavage (Lee, Ekker, Von Kessler, Porter, Sun & Beachy, 1994). This modification
is through the autocatalytic cleavage of the C-terminal domain, combined with
binding of a cholesterol moiety at this cleavage site (Mahindroo, Punchihewa & Fuji,
2009). In addition to cholesterol coupling, the ligand is further lipid modified via
palmitoylation of the N-terminal cysteine, giving rise to the active form of the Hh
ligand (Ingham & McMahon, 2001). In embryonic development, the cells
synthesizing Hh ligands are distinct from the Hh responsive cells that may be either
situated adjacent to, or at some distance from the Hh secreting cell (Varjosalo &
Taipale, 2007).
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In certain conditions the Hh secreting cells release Hh ligands into the extracellular
environment. They can then bind to the 12-span transmembrane protein receptor
Patched (Ptch) located on the surface of the Hh responsive cell that function as a
platform for intracellular signal transduction (Rietveld, Neutz, Simons & Eaton,
1999). In the absence of the Hh ligand, Ptch normally associates with the seventransmembrane span receptor-like protein Smoothened (Smo) at the cell membrane
and this interaction leads to inhibition of Smo dependent downstream intracellular
signalling (Ingham & McMahon, 2001). This inhibition leads to phosphorylation of
the glioma associated (Gli) zinc finger transcription factors that function downstream
of the Smo receptor. In vertebrates there are three distinct Gli proteins, Gli1, Gli2 and
Gli3 (Hui, Slusarski, Platt, Holmgren & Joyner, 1994), where Gli1 and Gli2 proteins
activate Hh target genes functioning as transcriptional activators, and Gli3 is thought
to act mainly as a transcriptional repressor (Choi, Omenetti, Syn & Diehl, 2010).
Gli2 is the primary mediator of Hh signalling, as genetic approaches show the
precedent role of Gli2 in Hh signalling for the induction of the Gli1 transcription
factor (Choi et al., 2010).

The Gli proteins are phosphorylated in the cytosol by protein kinase A (PKA),
glycogen synthetase kinase 3 (GSK3) and casein kinase (CSK) that targets them for
degradation in the cytosol by proteasomes, preventing their nuclear translocation and
transcription of the Hh target genes (Pan, Bai, Joyner & Wang, 2006; Pan, Wang &
Wang, 2008).

On the other hand, when the extracellular environment of the responsive cell is
enriched with Hh ligands, the Hh pathway is activated and the Hh ligand binds to the
Ptch receptor and this releases Smo leading to its activation (Metcalfe & De Sauvage,
2011). Activation of Smo prevents the phosphorylation of Gli transcription factors,
allowing their nuclear translocation and induction of transcription of Hh target genes
such as sfrp2, neo1 and c-myc (Pan et al., 2006; Pan et al., 2008).

In vertebrates, in the presence of Hh ligand, the mechanism by which the Hh signal is
transmitted from Smo to Gli transcriptional factors is not well understood. However
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in flies, the Hh ligand binding leads to localisation of Smo, and involves complexes
such as the serine threonine kinase fused (Fu), suppressor of fused (sufu) and
kinesin-like molecule Costal-2 (cos2) (Ogden, Ascano, Stegman, Suber, Hooper &
Robbins, 2003). The details of Gli activation remain obscure, however evidence
suggests that in the absence of the Hh ligand, Gli interacts with multiprotein
complexes such as sufu, but upon ligand binding the Gli proteins translocate to the
nucleus initiating transcription (Figure 1.3, Ogden et al., 2003). This shows that the
Hh signalling is regulated by positive and negative feedback mechanisms that are
tightly conserved across species (Ingham & McMahon, 2001). Despite this, it seems
to differentiate at some point amongst vertebrates and invertebrates (Varjosalo, &
Taipale, 2006). Vertebrates have an additional transmembrane protein, the Hedgehog
interacting protein (Hhip), which is also a Hh target gene. Hhip was discovered by
screening mouse complementary DNA (cDNA) expression libraries for proteins that
bind to Shh (Olsen et al., 2004). The Hhip competes with Ptch for binding to Hh
ligands, that is, it has an affinity equal to Ptch (Olsen, Hsu, Glienke, Rubanyi &
Brooks, 2004). Thus, when Ptch levels exceed that of Hh ligand, or when Hhip
sequesters Hh ligands, this can inhibit the Hh pathway (Olsen et al., 2004).

14

Figure 1.3: the active and inactive states of the Hh signalling pathway. In the
absence of the Hh ligand, inactive state (left), Ptch inhibits Smo, thus Gli is prevented
from entering the nucleus through interactions with cytoplasmic protein complexes
such as fused and sufu, and therefore transcription of the Hh target genes is
repressed. In the presence of Hh ligand, active state (right), binding of the Ptch to
Smo is released, leading to translocation of Gli to the nucleus, and Gli activates
transcription of the Hh target genes (reproduced from Magliano & Hebrok, 2003)

Recent studies in vertebrates have shown that Hh signalling requires a non-motile
cilium (Huangfu & Anderson, 2005). This was supported by genetic studies in mice
which showed that disruption of several anterograde or retrograde intraflagellar
transport components lead to limb and neural patterning defects caused by impaired
Hh signalling between Smo and Gli (Huangfu & Anderson, 2005). This provides
compelling evidence that activated mutations in these pathway components would
increase cell proliferation, a hallmark of tumour formation.

Although the role of Hh signalling in embryonic development is well established, its
functions in adult tissue repair and maintenance remains unclear. Additionally,
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several reports indicate that Hh signalling is an important regulator of stem cell
differentiation and maintenance.

1.5.3 Hh signalling and stem cells
A fundamental characteristic of stem cells is their ability to self-renew and generate
differentiated cells within different organs (Liu, Dontu, & Mantle, 2006). A number
of developmental pathways including Hh signalling have emerged as potentially
regulating the self-renewal processes of normal stem cells in the skin, breast, nervous
system and other haematopoietic systems (Taipale & Beachy 2001). Han et al.
(2008) indicated that Hh signalling via the primary cilia was essential for the
proliferation and maintenance of adult neural stem cells. Liu et al. (2006) studied the
role of Hh signalling for stem cell self-renewal and multilineage differentiation in
mammary glands. In normal breast development stem cells are capable of generating
epithelial components of the mammary gland. They showed that the Hh signalling
components Ptch, Gli1 and Gli2 were highly expressed in these human mammary
stem or progenitor cells using both in vitro cell cultivation and in vivo mouse
xenografts methods. Subsequently, they also showed that these genes were down
regulated when the progenitor cells were induced to differentiate.

The function of Hh signalling in the haematopoietic system was well demonstrated
by Zhao et al. (2009) whereby the Hh signalling receptor/modulator Smo was deleted
in haematopoietic cells and injected into mice to examine the effect. The mice
showed clear long term defects in the haematopoietic system. This loss of function
clearly identified the requirement of Smo and Hh signalling in the haematopoietic
cell self-renewal process in vivo. Forbes et al. (1996) identified that Hh protein is
produced by the cap cells which controls the maintenance of somatic follicle stem
cells. Subsequently, in another study conducted by Michel and colleagues (2012)
they showed that Hh is an essential niche signal for maintenance and differentiation
of somatic stem cells in the testis of a Drosophila.
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1.5.4 Hh pathway and cancer
Hh genes can induce cell proliferation, and this function of the Hh pathway
signalling is important in embryogenesis and tissue maintenance, but inappropriate
Hh pathway activation can lead to tumorigenesis. In recent years, it has become clear
that the aberrant activation of the Hh signalling pathway can lead to cancer, whereby
abnormal upregulation of the Hh ligand or deregulated expression of downstream Hh
pathway mediators is demonstrated. For example, loss of Ptch1 protein (Gailani,
Stahle-Backdahl, Leffell, Glynn, Zaphiropoulos, Pressman & Unden, 1996; Raffel,
2004) can cause activating mutations of Smo, which subsequently results in gene
disrupted Gli1 and Gli2 transcription (Xie, Murone, Luoh, Ryan, Gu, & Zhang,
1998).

The connections between the Hh pathway and cancer was first identified by the
observation that mutations in the Ptch1 receptor were associated with the rare
condition known as Gorlin’s syndrome (Johnson, Rothman, Xie, Goorich, Bare, &
Bonifas, 1996). Patients with this condition develop sporadic basal cell carcinomas
(BCCs) and are also at an increased risk of developing medullablastoma, a tumour of
the progenitor cells of the cerebellum. This link was further developed when a
majority of BCCs were observed with deletion and insertion mutations in the Ptch1
receptor protein; these mutations produce truncated proteins together with the loss of
heterozygosity (LOH) which inhibits the ability of Ptch to supress Smo resulting in
dysregulated Hh signalling (Xie et al., 1998). In addition, Gli1 protein
overexpression has also been noted in BCC like tumours in mice, establishing the
importance of Gli transcription in this tumorigenic process (Nilsson, unden, Krause,
Malmqwist, Raza & Zaphiropoulos, 2000).

Furthermore, many tumours exhibit autocrine, Hh ligand dependent, uncontrolled
pathway activation; examples of these types of tumours include, stomach, lung,
pancreas, prostate, brain, liver and breast (Kinzler, Bigner, Bigner, Trent, Law &
O’Brien, 1987; Yauch, Gould, Scales, Tang, Tian, & Ahn, 2008). Most of these
tumours demonstrate elevated Hh ligand or ectopic Ptch and Gli expression. A recent
study conducted by Yauch et al. (2008) highlighted that tumorigenesis by Hh
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signalling can occur through paracrine mechanisms. The epithelial tumours secret Hh
ligands into the tumour stroma, and this directly stimulates proliferation of the
mesenchymal cells. In another study, conducted by Fan and colleagues (2004) they
showed that prostate cancer signals to the stroma; this was evident through Hhinduced elevated Ptch and Gli expressions in murine stroma.

Aberrant activation of Hh signalling has also been reported in human small cell lung
cancer (SCLC) cell lines (Watkins et al., 2003). Activation of the Hh signalling
molecule Smo promoted the clonogenicity of human SCLC in vitro and subsequently
initiate and progress mouse SCLC in vivo (Park, Martelotto, Peifer, Sos, Karnezis, &
Mahjoub, 2011). Reciprocally, when Smo was deleted in mutant lung epithelial cells,
the initiation and progression of SCLC in mice was greatly supressed. Additionally,
following chemotherapy using pharmacological inhibitors of Hh signalling, these
mice showed inhibited SCLC growth (Park et al., 2011). These roles of Hh signalling
in SCLC demonstrate crucial functions in the development and maintenance of
SCLC. Effects of Hh signalling blockage were also demonstrated by Berman et al.
(2003), where cyclopamine (a compound that interferes with Smo activity preventing
Hh induced Gli expression) treatment in murine medulloblastoma cells blocked cell
proliferation and also induced changes in gene expression, thus establishing a
specific role for Hh signalling in medullolastoma growth.

The Gli transcription factors also regulate several cellular functions in malignant
transformation such as cell cycle progression and apoptosis (Dennler, Andre,
Alexaki, Li, Magnaldo, & Dijke, 2007). High levels of Gli1 expression have been
noted in human Glioblastoma (Kinzler et al., 1987), and these high levels of Gli1
were also expressed in other varieties of glial tumours, with Gli1 overexpression
leading to hyper-proliferation of the central nervous system (Dahmane, Sanchez,
Gitton, Palma, Sun, & Beyna, 2001). Overexpression of Gli1 has also been identified
in a variety of brain tumours ranging from low-grade to high-grade. This was evident
in a study that identified overexpression of the Hh mediator Gli1 (Clement, Sanchez,
Tribulet, Radovanovic & Altaba, 2007). Furthermore, inhibiting Gli1 expression
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using small interfering RNA, affected cell proliferation in primary cultures of these
tumour cells (Clement et al., 2007).

Recent evidence now indicates that deregulated tumour formation not only promotes
tumour formation but is also required for tumour maintenance. This is evident in
transformed cells that continue to require Hh activity for growth and survival. This
was shown in a study conducted by Thayer et al. (2003) where all of the 26
pancreatic adenocarcinoma cell lines expressed Hh target genes. Furthermore,
treatment of tumour cells with cyclopamine induced apoptosis and loss of
proliferation in more than half of these cell lines. In support, a previous study
conducted by Dahmane et al. (2001) a subset of Glioma cell lines responded to
cyclopamine-mediated inhibition of Hh signalling. Similarly, other digestive tract
derived tumours such as stomach and oesophagus showed increased levels of Hh
pathway signalling, and as expected these cell lines were also susceptible to
cyclopamine-mediated inhibition of tumour growth (Berman et al., 2003).

It is believed that tumour growth might depend on some cancer stem cells (CSCs)
which are similar to normal stem cells, and regulate the same signalling molecules as
normal stem cells. Increasing evidence supports the concept that abnormal formation
and growth of cancer is due to deregulated signalling pathways in stem cells
including the Hh pathway (Rubin & De Sauvage, 2006). Studies have shown that Hh
signalling regulates self-renewal of CSC in breast, glioma and multiple myeloma
(Clement et al., 2007). Self-renewal is required for the maintenance of malignant
clones as reported in mouse models of chronic myeloid leukaemia (CML) which
provides evidence that Hh signalling regulates this self-renewal property (Peacock et
al., 2007). In this study, genetic disruption of Smo activity leading to loss of Hh
signalling, lead to the inhibition of BCR-ABL (tyrosine-kinase inhibitor, first line
therapy for patients with chronic leukaemia) expressing leukaemia stem cells and
prolonged survival (Peacock et al., 2007). Active Hh signalling has also been
identified in Glioblastoma CSCs, where the use of pathway inhibitors such as
cyclopamine or siRNA (small interfering RNA) specifically targeting pathway
components resulted in loss of tumorigenesis (Clement et al., 2007). Similarly, in

19

breast cancer, stimulating the activation of Hh pathways in CSCs using the Hh ligand
and Gli1 or Gli2, or on the other hand inhibiting Gli1 or Gli2 expression using
specific siRNA, altered the expression of BMI-1, which is a self –renewal regulator
in normal stem cells (Liu et al., 2006).

CSCs have also been implicated in tumour progression and metastases development
in solid tumours, and again Hh signalling has been reported to be playing a critical
role in these processes (Mani, Guo, & Liao, 2008). For example, in colon carcinomas
derived from primary clinical specimens, the Hh activity within the CSCs was
evident by high expressions of Gli1, Gli2 and Ptch in their cellular compartments
(Mani et al., 2008). Moreover, inhibiting Hh pathway activity in these cells with
cyclopamine or siRNA to Gli1, Gli2, and Smo, reduced tumour cell proliferation and
induced apoptosis (Mani et al., 2008). Furthermore, using short hairpin RNA
(shRNA) against Smo eliminated metastatic development in these tumours. Tumours
contain only small amount of CSC are typically resistant to chemotherapy and
radiation because they are slow growing cells (Beachy, Karhadkar & Berman, 2004).
The fact that Hh signalling has been identified in several types of CSCs would mean
that inhibiting Hh signalling is a promising therapeutic target to deplete tumour
forming CSCs.

It is certain that different components of the Hh pathway play pivotal roles in the
biology of different cancers, and amongst these the Gli transcription factor especially
Gli2, plays a predominant role. Kim et al. (2007) demonstrated that selective downregulation of Gli2 inhibited proliferation of hepatocellular carcinoma cells (HCC),
inhibited expression levels of cell survival markers such as Bcl-2 and c-Myc, and
enhanced expression levels of cell cycle inhibitor marker p27. Subsequent studies
following this showed that high expression of Gli2 in HCC tissues is associated with
poor prognosis in patients (Zhang et al., 2013).
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1.5.5 Hedgehog pathway and MM
Similar to other cancers, development of MM is considered to be a multi-step
process that reveals mutations in different genes. These genes are commonly
involved in growth and are regulated by pathways including the Hh signalling
pathway (Greillier & Astoul, 2008). The aberrant expression and inappropriate
activation of the Hh pathway has induced many cancers including non-small cell
lung cancer and Medulloblastoma (Dennler et al., 2007). However, the significance
of aberrant Hh pathway signalling in the development and growth of MM still
remains to be determined.

A recent study conducted by Shi et al. (2012) was the first to document a role for Hh
signalling in MM cell growth. They observed an increased expression of Ptch1, Gli1,
Shh and Hhip in frozen tumour tissues from 39 MPM patients suggesting activation
of the Hh pathway. They observed that high Gli1 expression levels were associated
with poor patient survival. They then expanded their investigation to examine the
activity of the Hh signalling pathway in MPM tumours, and the effects of inhibiting
this pathway in primary mesothelioma cell cultures and in a mouse xenograft model.
Activation of the pathway was also demonstrated in MM cells, as blocking Hh
signalling with cyclopamine resulted in a downregulation of Gli1 expression in more
than half the cell lines examined.

In vivo analysis using MPM xenografts (transplantation of cells from one species to
another) determined that expression of Dhh correlated with human Gli1 and Ptch1
expressions, which suggests autocrine Hh activity in some MPM. Treatment of two
primary MPM cultures obtained from xenografts in mice with Hh antagonist resulted
in a dose dependent decrease of cell survival, indicating the role of Hh signalling in
MPM growth. They also showed that inhibitors targeting Smo could decrease Gli
expression and cell growth and subsequently, decreased cell proliferation in cell
cultures. In conclusion, this study identified an upregulation of Hh signalling in
MPM tumours. Additionally, observing that Smo inhibitors decreased cells growth
both in vitro and in vivo.
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Li et al. (2013) in a current study reported an essential role for Gli transcription
factors in MPM tumour growth. They showed that a majority of MPM tumour tissues
had significant higher levels of Gli1, Gli2 and their downstream target genes, and by
inhibiting Gli1 and Gli2 using specific siRNAs, supressed MPM cell proliferation in
vitro and in vivo, thus highlighting Gli1 and Gli2 as important and potent therapeutic
targets in MPM.

Hh signalling is unlikely to be a sole effector pathway in tumorigenesis and there is
growing evidence to suggest that it works with several other oncogenic factors for
tumour formation, including growth factors such as TGF-β. Similar to the Hh
members, TGF-β has emerged as an important molecule to be involved in various
physiological processes and under appropriate conditions contributes to the
aggressiveness and neoplastic progression in a variety of tumour types.

1.6 TGF-β
TGF-β is a multifunctional peptide that was first identified for its ability to cause
phenotypic transformation of rat fibroblasts (Sporn, Robers, Wakefield & Assoian,
1986). TGF-β has subsequently been shown to have various regulatory actions in a
variety of normal and neoplastic cells, by regulating several functions including
growth, differentiation, proliferation, adhesion and apoptosis (Sporn et al., 1986).
TGF-β’s are important regulators of diverse developmental processes and
homeostasis, and disruption of their activity has been implicated in a variety of
human diseases including cancer (Sporn et al., 1986). More than 30 proteins have
been identified as members of the TGF-β superfamily, including activins and bone
morphogenic proteins (BMP) (Sporn et al., 1986). There are three mammalian TGFβ isoforms, TGF-β1, TGF-β2 and TGF-β3 and are synthesised by a wide variety of
cell types including platelets, macrophages, fibroblasts and tumour cells (Savage,
Das, Finelli, Townend, Sun, Baird & Padgett, 1996).
TGF-β was initially discovered in normal rat kidney fibroblasts, where TGF-β was
measured for its ability to stimulate proliferation, and could also transform rat kidney
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fibroblasts (Sporn et al., 1986). However, other contradicting studies also showed
that TGF-β was essentially identical to a previously identified growth inhibitor,
which was characterised in monkey kidney cells and which inhibited cell
proliferation through autocrine mechanisms (Savage, Das, Finelli, Townend, Sun,
Baird & Padgett, 1996). In support, Moses et al., 1987 showed that TGF-β is
involved in the mitogenic process of fibroblasts, where it inhibits epithelial and
endothelial cell proliferation in vitro. Other regulatory functions of TGF-β include
initiating a cascade of events leading to neovascularization and matrix synthesis
(Latterio, Geiser, Kulkarni, Roche, Sporn & Roberts, 1994), transport of glucose and
amino acids, and glycolysis in fibroblasts, with a more specific action of enhancing
fibronectin and collagen production in these cells (Smith et al., 1999). Thus the
application of TGF-β to connective tissues, leads to fibrosis and angiogenesis (Sporn
et al., 1986), suggesting that it may have application in tissue repair caused by
trauma.

1.6.1 Regulation of TGF-β
TGF-β is synthesized as a large precursor protein which is then cleaved to generate
mature the ligand (Mehra & Wrana, 2002). This pre-protein is about 100kDa in size
and consist of an amino terminal and a mature carboxyl terminal (Gentry, Lioubin,
Purchio & Marquardt, 1988). Cleavage is mediated by furins-which are pro-proteins
that process latent TGF-β into biologically active forms (Matthews, Goodman,
Gorman & Wells, 1994). The cleavage pro-region for TGF-β, also known as latency
associated peptide (LAP), remains non-covalently bonded to the mature peptide to
form a latent TGF-β complex. Thereafter, the latent TGF-β complex is secreted and
undergoes further processes in the extracellular matrix (Thomsen & Melton, 1993).
Various different cells synthesize TGF-β and essentially all have high affinity
receptors for this peptide (Sporn et al., 1986).
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1.6.2 TGF-β receptors
The TGF-β ligand binds to several specific cell membrane receptors. These
membranes are of high affinity and are founds in essentially all normal and
malignant, epithelial and mesenchymal cells (Clark & Coker, 1998). These
transmembrane surface receptors carry TGF-β signal into the cell. Massague and
colleagues 1998, characterised TGF-β receptors, whereby radioactively labelled
TGF-β was cross linked with cell surface proteins which revealed that TGF-β binds
to three types of receptors and were named as type I, II, and III receptors.

Type I and II receptors are glycoproteins of 55 kDa and 70 kDa respectively, with a
core polypeptide of around 500-570 amino acids (Massague, 1998). The receptors
have a relatively short extracellular region (approximately 150 aminoacids), Nglycosylated, and around ten or more cystines which determine the general fold in
that region, and three of these cystines form a cluster near the transmembrane
sequence (Ebner, Chen, Shum, Lawler & Zoncheck, 1993). Lin and colleagues
(1992), identified type II receptor with preferentially bound activin and TGF-β1
through expression cloning. The type I receptor has received many names. It is
generally referred to as activin receptor like kinase (ALK) (Clark & Coker, 1998) or
TβRI. Whereas type II receptor subfamily that specifically binds to TGF-β is known
as TβRII (Wrighton, Lin & Feng, 2009). In contrast to type I and type II receptors,
type III plays an ancillary role, whereby they modulate their activity by regulating
ligand access to type I and type II.

The receptors comprise of an intracellular kinase domain which phosphorylates
serine and threonine residues (Ebner et al., 1993). Signalling is initiated when the
TGF-β ligand binds to the type II receptor, that interacts with a specific type I
receptor (ALK5/TβRI) forming the mature signalling complex (Moustakas, Lin,
Henis, Plamondon, O’Connor-McCourt & Lodish, 1993) Figure 1.4. This formation
of ligand induced receptor complex leads to the phosphorylation of the type I
receptor which activates the SMAD proteins that carry the signal to the nucleus and
initiate transcription of the target genes (Ebner et al., 1993).
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Figure 1.4: Interaction of TGF-β ligand with its type I and type II receptors. The
phosphorylation step induces transduction pathway (reproduced from Attison &
Wrana, 2002).

1.6.3 SMAD signalling pathway
After type I and II receptor activation, TGF-β signalling is mediated by the SMAD
signalling pathway (Padgett, 1999). The SMAD proteins were named after the
homologous proteins referred to as the Mad gene in Drosophila and the sma gene
from C. elegans (Derynyck, Gelbart, Harland, Heldin, Kern & Massague, 1996). The
first experimental evidence that SMADs functions downstream of receptors was
performed through genetic mosaic analysis in C.elegans (Savage et al., 1996).
Thereafter, eight different SMAD proteins were identified, divided into three
functional categories: the receptor regulated SMADs (R-SMAD), common SMADs
(co-SMAD) and inhibitory or antagonistic SMADs (I-SMAD). The intracellular
proteins R-SMADs and co-SMADs are composed of three parts: the highly
conserved Mad homology 1 and 2 (MH1 and MH2), N-terminal and a C-terminal.
The I-SMADs are similar, except they have poorly conserved MH1 domain
(Massague, 1998).

The R-SMADs (SMAD 1, 2, 3, 5 and 8) are phosphorylated by the type I receptors.
The phosphorylation of the R-SMADS forms a complex with the co-SMAD, of
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which SMAD4 is the only member (Massogue, Blain & Lo, 2000). The co-SMAD
works as a co-activator or a co-suppressor, thereby possibly regulating positive and
negative gene expression. In contrast, the I-SMADs (SMAD 6 and 7), act as
antagonizing SMADs counteracting the effects of R-SMADs Figure 1.5 (Massague,
1998). These three SMAD groups represent the signalling pathway for TGF-β, which
transmits signals from the receptors to the nucleus to regulate transcription activity of
TGF-β target genes (Massogue et al. 2000).

Figure 1.5: The SMAD family members from vertebrates indicating highly
conserved MH1 and MH2 collaborates with co-SMADs. The antagonistic SMADs
counteract that activation (reproduced from Massague, 1998).

1.6.4 TGF-β Signal transduction through the SMAD pathway
TGF-β1 is the most abundant and most expressed isoform (Elliot & Blobe, 2005).
TGF-β is secreted into the extracellular matrix as a latent protein complex, which is
then modified into a biologically active form (Padgett, 1999). A cellular response is
achieved when the activated TGF-β binds to receptor specific TBRII and
ALK5/TβRI, which in turn initiates phosphorylation of the intracellular receptor
regulated SMADs, SMAD2 and SMAD3 (Elliot & Blobe, 2005). These
phosphorylated SMADs heterodimerise with the co-SMAD, SMAD4 forming a
complex, which then translocate to the nucleus (Elliot & Blobe, 2005). Accumulation
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of this SMAD complex in the nucleus initiates transcription of the TGF-β target
genes (Figure 1.6, Elliot & Blobe, 2005). SMADs 1, 6 and 8 are activated in
response to bone morphogenic proteins (BMP) signals.

Figure 1.6: the TGF-β SMAD signalling pathway showing binding of the TGF-β to
their receptors and downstream SMAD signalling (reproduced from Elliot & Blobe,
2005).
Some studies suggest that TGF-β receptors can interact with a number of proteins,
activating other signalling pathways. TGF-β induced signals are either transduced in
SMAD-dependent (canonical) or SMAD-independent (non-canonical) pathways
(Padgett, 1999; Massague, 1998).

1.6.5 Non-canonical TGF-β signalling pathways
Although TGFβRI & RII and SMADs comprise the TGF-β signalling pathway, other
non SMAD pathways have been identified that signals through TGF-β, such as
mitogen activated protein kinase (MAPK-JNK/ERK) (Engel, et al., 1999; Fink et al.,
2001), Rho guanosine triphosphatase and PI3 kinase/Akt (Figure 1.7, Bhowmick et
al., 2001), Evidence of TGF-β activating the MAPK pathway came from cells
overexpressing dominant negative SMAD4 and SMAD4-deficient cells. In these
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cells, activation with JNK/MAPK was enough to elicit TGF-β regulated response
(Engel et al., 1999). The precise molecular mechanisms by which TGF-β activates
MAPK remains unclear however, evidence suggests that in epithelial cells activation
of ERK is involved in TGF-β mediated Ras signalling (Bhowmick et al., 2001;
Zhang, 2009). Similarly, TGF-β induced epithelial to mesenchymal transition (EMT)
involves non-SMAD pathways, signalling via the PI3K/Akt pathway (Bhowmick et
al., 2001). These multistep SMAD and non-SMAD pathways activated by TGF-β
involves a complex mechanism. A greater understanding of this TGF-β mediated
pathways in different cell types and in the context of specific environments might
provide insights into TGF-β signalling in various cancers including MM.

Figure 1.7: Representation of canonical and non-conical TGF-β signalling pathways
(reproduced from Chaudhury & Rowe, 2009).

1.6.6 Role of TGF-β in cancer
TGF-β is an essential regulator of cellular and physiological processes, and
alterations in the TGF-β signalling pathway and resistance to inhibition of
proliferation is frequently observed in cancers. TGF-β function both as an anti-
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proliferative factor and as a tumour promoter, and various components of the TGF-β
signal transduction pathway that normally act as tumour suppressors, are mutated in
different cancers (Massogue et al., 2000). Functional loss of TGF-β and its
association with tumorigenesis has been demonstrated in gastric and colon
carcinomas with somatic mutations in the type II TGF-β receptor (Suzuki et al.,
2004). Pancreatic, lung and breast are other cancers identified carrying mutations in
the TGF-β signalling pathway components (Suzuki et al., 2004). Therefore, these
diverse activities have promoted investigation to broaden the understanding of how
TGF-β family members signal to evaluate diagnostic, prognostic and predictive
markers for cancer patients.

1.6.7 TGF-β signalling in MM
There is strong evidence to support the involvement of TGF-β in MM growth.
Firstly, significant levels of TGF-β are produced by most human (Fitzpatrick et al.,
1994; Shetty et al., 2009) and murine MM cell lines (Kuwahara et al., 2001). In
addition MM patients have been documented with high levels of TGF-β, whereby
immunoreactivity to TGF-β was observed in more than 90% MM patients (Jagirdar,
Lee, Reibman, Gold, Aston & Begin, 1997). Maeda et al. (1994) measured TGF-β
levels in pleural effusions from MM patients, which was approximately 280 pmol/L,
nearly three times greater compared to pleural effusions from primary lung cancer
patients and nearly six times higher compared to pleural effusions from non-small
cell lung cancer (NSCLC) and breast cancer patients (Suzuki et al., 2004).
Secondly, involvement of TGF-β in MM pathogenesis has been observed in several
studies. Fitzpatrick et al. (1994) transfected mouse MM cells with antisense RNA to
TGF-β1 and TGF-β2 and observed a delay in tumour growth when these transfected
MM cells were adoptively transferred to recipient animals. These findings were
supported by Marzo et al. (1997) who demonstrated that administration of TGF-β2
antisense oligonucleotides in vivo reduced tumour growth in a MM animal model.
Thirdly, there is evidence to suggest that TGF-β may potentially respond to
immunological therapy. Suzuki et al. (2004) explored the effects of a soluble TGF-β
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type II receptor (sTGF-βR) which specifically inhibits TGF-β1 and TGF-β3 isoforms
(Smith et al., 1999) in AB12, AC29 and AB1 murine MM tumour models. AB12 and
AC29 cells produce large amounts of endogenous TGF-β whereas AB1 did not
(Christmas, Manning, Garlepp, Musk & Robinson, 1993).

sTGF-βR treatment

inhibited AB12 and AC29 tumour growth in mice. In contrast, AB1 growth was not
affected by sTGF-βR treatment. Thus blocking of TGF-β is a promising anticancer
therapy to treat MM patients.

In recent years there has been a strong focus on examination of signalling pathways
in promoting tumour growth, which has lead to various anticancer treatments being
developed. Most current therapies aim at blocking these signalling pathways.
However, not all tumours are responsive to these inhibitors, and some tumours that
may be responsive initially, become resistant during the course of the treatment.
Therefore, there is need to develop a broader understanding of the regulation of
signalling pathways in tumorigenesis process of various cancers to develop better
therapeutic approaches.

Researchers are now exploring the interaction or cross talk between different
signalling pathways in tumour growth. Initially, studies examined the effect of
interacting signalling pathways on cellular functions, particularly in embryonic
developmental and physiological processes. Recently, studies have looked at
pathway interactions and how they are regulated in tumorigenesis.

1.7 TGF-β cross-talk with Wnt and Hippo signalling pathways
An example of these interacting pathways is between the TGF-β and Wnt signalling
pathways. Attisano and Labbe. (2004) demonstrated that TGF-β and Wnt ligands can
co-orporate to regulate cell differentiation and control gene expression patterns, and
described their co-orporation in promoting tumorogenesis in mice.

Wnt proteins are secreted glycoproteins that are important in various developmental
processes including the formation of body axis during early embryogenesis (Moon,
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Bowerman, Boutros & Parriman, 2002). In addition to its developmental role,
inappropriate activation of the Wnt pathway has been implicated in various cancers
(Cadigan & Nusse, 1997). β-catenin is the key component of the Wnt signalling
pathway. In the absence of the Wnt ligand, the pathways intermediate molecules
such as APC (Adenomatous Polyposis Coli), axin and GSK3 (Glycogen Synthase
Kinase 3) forms a complex that results in phosphorylation and degradation of βcatenin, however, in the presence of Wnt ligand, this ligand binds to frizzled proteins
which then stabilizes β-catenin, and accumulates in the nucleus associating itself
with LEF1/LCF transcriptional factors to regulate target gene expression (Skromne
& Stern, 2001). Mouse models have provided an insight into the cross-talk between
TGF-β and Wnt signalling pathways, disrupted TGF-β signalling in the context of
activated Wnt promoted tumorigenesis (Skromne & Stern, 2001). TGF-β signals
through the SMAD pathway and Takaku and colleagues 1998, isolated SMAD4/APC
heterozygotes and showed that these mice developed more severe form of malignant
tumours from intestinal polps compared to mice with just the APC. In another study,
SMAD4/APC heterozygote mice were challenged with carcinogens and these mice
developed significant numbers of pancreatic acinar foci compared to the control APC
mice (Cullingworth, Hooper, Harrison, Mason, Sirard, & Patek, 2002).

Similarly, interactions between TGF-β and Hippo signalling pathways have been
noted in some cancers, including MM, whereby mutations in the Hippo cascade were
observed in MM cases which then negatively regulated its pathway mediators. The
Hippo signalling pathway controls organ size in animals by regulating cell
proliferation and apoptosis (Hall, Wang, & Miao, 2010). This pathway induces
expression of several organ growth genes such as cyclin E. Yes-associated proteins
(YAP) human homolog is a key transcriptional target of the Hippo pathway (Hall et
al., 2010). YAP plays a conserved role in the tumorigenic processes of various
cancers. Fuji et al. (2012) observed a functional interaction between TGF-β and
Hippo pathway in regulating connective tissue growth factor (CTGF). There was an
induced CTGF expression in MM cells by the formation of YAP-TEAD4-SMAD3p300 complex on the CTGF promoter (Fuji et al., 2012). In support, xenografted
mice showed a prolonged survival rate when the CTGF expression was knocked
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down in MM cell, suggesting CTGF as an important modulator of MM growth and
pathology, providing a novel therapeutic approach for MM (Fuji et al., 2012).
Functional interaction between TGF-β and Hh signalling in cancers has also been
identified by several investigators. TGF-β and Hh are involved in numerous
overlapping processes during embryonic development and several studies have
identified this interaction in cancers.

1.8 Interaction between Hh and TGF-β signalling pathways
As described earlier, the transcriptional response to Hh signalling is mediated by the
Gli transcriptional factors. Gli regulates several cellular functions linked to malignant
transformation, such as cell cycle progression, differentiation and apoptosis (Kasper,
Frischauf & Abager, 2006). Also mentioned previously was the essential role of
TGF-β essential in physiological processes including tissue repair, control of cell
growth, differentiation and immune regulation. Subsequently, expression of TGF-β
isoforms contributing to the severity and progression of neoplasms have also been
identified in various tumour types (Derynck et al., 1996). Recent studies have shown
that Gli is not solely regulated by Hh signalling but also by other pathways such as
TGF-β. Studies have examined the capacity of TGF-β to affect the expression of Hh
signalling molecule Gli1 and Gli2 in vitro and in vivo.

Dennler et al. (2007) identified Gli2 as the most transcriptionally active of the Gli
proteins and a target of TGF-β/SMAD signalling, independent of the Hh signalling
pathway. The capacity of TGF-β to rapidly induce Gli2 expression in the presence of
Hh inhibitor cyclopamine, revealed this pathway interaction. Interestingly, Gli1 is
also induced by TGF-β but in a Gli2-dependent manner which was also independent
of Hh signalling. In vitro studies confirmed Gli1 and Gli2 expressions induced by
TGF-β in various cell types including breast carcinoma cells, human dermal
fibroblasts, cutaneous melanoma, glioblastoma and keratinocytes. These findings
were supported by in vivo studies, where transgenic mouse models overexpressing
TGF-β1 activated Gli1 and Gli2 expression in a SMAD3 dependent manner. Finally
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they showed TGF-β induced Gli1 and Gli2 expression was greatly inhibited
inhibitors such as ALK5 inhibitors and transfected Gli2 siRNA oligonucleotides in
cyclopamine resistant pancreatic adenocarcinoma cell lines (Dennler et al., 2007).
Yoo, Kang, Kim and Oh. (2008) investigated the role of Shh and TGF-β signalling in
the metastatic process of human gastric cancers by examining ALK5 and Gli
immunohistochemical staining on tumour biopsies from gastric cancer patients.
ALK5 and Gli expression was classified as strong in 2% and 48% of biopsies
respectively, Figure 1.8.

Figure 1.8: Gli immunohistochemical stain x 200, Gli highly expressed in an area of
gastric tissue (light brown staining) (reproduced from Yoo et al., 2008)

Several independent groups have confirmed induction of Gli, specifically Gli2 by
TGF-β. Hu and colleagues, (2004) found that TGF-β signalling increased Gli2
expression, which then influenced the progression from ductal carcinoma in situ to
invasive carcinoma. These findings were consistent with the findings of Alaxaki et al
(2010), who found that TGF-β increased Gli2 expression which subsequently
increased its downstream target Gli1 and this influenced cell differentiation and
progress of myoepithelial cell to invasion. Edson and colleagues, (2010) found that
in normal granulosa cells, Gli2 is a TGF-β-regulated gene and suggested that Gli
may contribute to cancer progression in the ovary. Furthermore, a recent study by
Johnson et al. (2010) observed that blocking Gli signalling with a Gli2 repressor
gene in metastatic breast cancer cells reduced TGF-β-induced parathyroid hormone
mRNA expression, thereby reducing tumour-induced bone destruction. TGF-β is a
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molecule shown to be important in MM, however the aberrant activation of Hh
signalling and the interaction of its mediators with TGF-β remains to be determined.
While TGF-β contributes to the biological effects of the Hh pathway and its
mediators, it is also highly likely that the Hh pathway could induce TGF-β activity.
This opposite action was evident in non-small cell lung cancer (NSCLC), where
pharmacological inhibitors of the Hh pathway were shown to inhibit TGF-β-induced
epithelial to mesenchymal transition (EMT) (Maitah, Ali, Ahmed, Gadgeel & Sarkar,
2011). Hh and TGF-β signalling can form a vicious cycle where it can promote
tumour growth and development in cancers. However the interaction between these
pathways in MM is unknown.

1.9 Scope of thesis
Numerous studies have shown abnormal Hh signalling in various cancers. Similarly,
TGF-β signalling aids to the pathogenesis in many cancers including MM. However,
only a few studies have examined the interaction between the two pathways in cancer
and there have been no published studies examining their interaction in MM. Current
treatment regimens in MM are largely unsuccessful. Therefore, new innovative
treatments such as molecular targeted approaches needs to be developed.

Previous studies by our laboratory and others have shown the contribution of TGF-β
in MM. Our laboratory is now investigating the importance of Hh signalling in these
cells. Importantly, we now have preliminary data suggesting that TGF-β affects the
downstream effector molecules of the Hh pathway in MM cells. Its important then to
understand how the TGF-β and Hh pathways interact and what regulates these
pathways may identify novel targets for therapeutic intervention.

1.9.1 Research Direction
1.9.1.1 General Hypothesis
TGF-β induces Gli1 and Gli2 expression in MM cells through activation of the
SMAD signalling pathway.
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1.9.1.2 Aims
Aim 1. To examine the effect of TGF-β1 and TGF-β2 on the expression of Gli1 and
Gli2 in MM cells.
(a) Determine the levels of endogenous TGF-β1 and TGF-β2 mRNA in MM
and control cell lines.
(b) Validate the activity of recombinant TGF-β1/2 by measuring pSMAD2
proteins and human collagen type-1α1 mRNA expression in MM and control
cells.
(c) Examine the effect of TGF-β1 and TGF-β2 on Gli1 and Gli2 mRNA levels
in MM and control cells.

Aim 2. To determine if TGF-β-induced Gli mRNA is independent of the Hh
signalling pathway and examine the effects of blocking TGF-β on Gli1 and Gli2
mRNA levels.
(a)

Evaluate the effect of blocking ALK5 inhibitor (SB-431542) on TGF-

β1 and TGF-β2 mediated Gli1 and Gli2 mRNA levels.
(b)

Evaluate the effect of ALK5 inhibitor on SMAD2/3 protein

expression
(c)

Examine the effect of TGF-β1 and TGF-β2 on Gli1 and Gli2 mRNA

levels in the presence of a Smo inhibitor
Aim 3. To determine the signalling pathway through which TGF-β regulates Gli1
and Gli2 expression.
(a)

Effect of TGF-β stimulation on SMAD2/3 protein expression

Determine if TGF-β-induced Gli mRNA is mediated through the SMAD2/3
pathway.

To address aim 1 a) I will measure mRNA expression of TGF-â1/2 in MM, control
cells (MeT-5A) and primary mesothelial cells by real-time PCR. In aim 1 b) I will
isolate RNA and protein from MM and MeT-5A cells after TGF-â1/2 stimulation and
measure phosphorylation of SMAD2 proteins and human collagen type-1α1 mRNA
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levels. In aim 1 c) I will isolate RNA from MM and MeT-5A cells after TGF-â1/2
stimulation and measure Gli1/2 mRNA levels by real-time PCR.

For aim 2 and 3, based on aim 1(c) I will choose 1 MM and MeT-5A cell line for
subsequent studies.

In aim 2 a) I will isolate RNA and protein from a 1 MM and MeT-5A cell lines after
SB-431542 and TGF-β1/2 treatment. The expression of Gli1/2 mRNA levels will be
measured by real-time PCR. In aim 2 b) the effectiveness of SB-431542 to inhibit
TGF-β1/2 will be confirmed by SMAD2/3 protein expression by western blot
analysis. For aim 2 c) cells will be pretreated with Hh pathway inhibitor
cyclopamine, then stimulate with TGF-β1/2 and isolate RNA to measure Gli1/2
mRNA levels by real-time PCR.

For aim 3 a) the effectiveness of the siRNA to delete SMAD pathway will be
confirmed by measuring SMAD2/3 mRNA and pSMAD2 protein by real-time PCR
and western blot analysis respectively. Thereafter, I will isolate RNA and protein
from a 1 MM and MeT-5A cell line that have been transfected with SMAD2/3 and
control siRNA and treated with TGF-β1/2. The expression of Gli1/2 mRNA will be
measured using real-time PCR.
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Chapter 2
Materials
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2.1 Reagents
2.1.1 Tissue culture
Dulbecco’s modified eagle’s medium

GIBCO® Life Technologies™

(DMEM)

Mulgrave, Victoria, Australia

Foetal calf serum (FCS)

SAFC Bioscience
Brooklyn, Victoria, Australia

Gentamycin {10mg/ml}

GIBCO® Life Technologies™

L-glutamine (L-Glut) {200mM}

GIBCO® Life Technologies™

Penicillin {10 000 units (U)/mL}

GIBCO® Life Technologies™

/Streptomycin {10 000 µg/mL} (P/S)
GIBCO® Life Technologies™

Trypsin-EDTA {0.25%}

2.1.2 Reverse transcription (RT-PCR)
Omniscript reverse transcription kit

Qiagen® Chadstone, Victoria, Australia

Deoxyribonucleoside triphosphates

Qiagen®

(dNTPs) {5mM}
Omniscript reverse transcriptase {4U/µl}

Qiagen®

Reverse transcriptase buffer {10x}

Qiagen®

RNase inhibitor {4U/µl}

Qiagen®

Random hexamers {3 µg/µL}

Life Technologies™

2.1.3 Real-Time Polymerase Chain Reaction (PCR)
Quantifast™ Probe PCR Master Mix {2x} Qiagen®
Life Technologies™

Taqman® Universal PCR Master Mix

2.1.4 RNA Isolation
Purelink™ RNA Mini Kit

Life Technologies™

RNeasy Mini Kit

Qiagen®

RNase Free DNase Set

Qiagen®
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2.1.5 Protein Isolations
Aprotonin

Sigma-Aldrich®
Castle Hill, NSW, Australia

β-glycerophosphate

Sigma-Aldrich®

Dithiothreitol

Sigma-Aldrich®

EDTA

Life Technologies™

HEPES

Sigma-Aldrich®

Leupeptin

Sigma-Aldrich®

Magnesium Chloride (MgCl₂)

Life Technologies™

Nonyl phenoxypolyethoxylethanol (NP40) Sigma-Aldrich®
Phenylmethanesulfonylfluoride (PMSF)

Sigma-Aldrich®

Sodium fluoride (NaF)

Sigma-Aldrich®

Sodium molybdite dehydrate (NaMolyb)

Sigma-Aldrich®

Sodium orthovanadate (Na₃VO₄)

Sigma-Aldrich®

Sodium pyrophosphate decahydrate (NaPyr) Sigma-Aldrich®
Triton®X-100

Sigma-Aldrich®

2.1.6 Western blot
Acrylamide
Ammonium per sulfate

BIO-RAD Gladsville, NSW, Australia
(APS)

BIO-RAD

Bromophynol blue

Sigma-Aldrich®

Coomassie Plus™ Protein Assay Kit

Thermo Scientific
Scoreby, Vic, Australia

Immobilon western HRP substrate

Millipore Klisiyth, Victoria, Australia

Instant Skim milk powder

Diploma Instant
Balcatta, WA, Australia

Nitrocellulose membrane

Whatman® Dassel, Germany

Precision plus protein™

BIO-RAD

dual colour standard
Sodium dodecyl sulphate (SDS)

Sigma-Aldrich®

Tetramethylethylenediamine (TEMED)

Sigma-Aldrich®

Polyvinylidene fluoride (PVDF)

Millipore
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membrane
Tween-20®

Sigma-Aldrich®

2.1.7 Alphascreen® Surefire® Assay
GAPDH Surefire® Assay kit

Perkin Elmer Life Sciences®
Massachusetts, U.S.A

Histone Surefire® Assay kit

Perkin Elmer Life Sciences®

pSMAD2 Surefire® Assay kit

Perkin Elmer Life Sciences®

Protein A acceptor beads

Perkin Elmer Life Sciences®

Streptavidin coated donor beads

Perkin Elmer Life Sciences®

2.1.8 Other reagents
Absolute ethanol

Thermo Fisher Malaga, WA, Australia

β- Mercaptoethanol

Sigma-Aldrich®

Bovine serum albumin

Sigma-Aldrich®

Dimethyl sulfoxide (DMSO)

Sigma-Aldirch®

Double deionised H₂O

Sigma-Aldrich®

Glycerol

Sigma-Aldrich®

Glycine

Sigma-Aldrich®

Lipofectamine™ 2000

Life Technologies™

Methanol

Chem Supply Gillman, SA, Australia

Sodium chloride (NaCl)

Sigma-Aldrich®

Tris-base

Sigma-Aldrich®

2.1.9 Antibodies
Anti-α-tubulin monoclonal primary

Sigma-Aldrich®

antibody produced in mouse
Secondary polyclonal anti-rabbit

Dakocytomation

immunoglobulins/HRP

Campbellfield, Vic, Australia

Secondary polyclonal anti-mouse

Dakocytomation

immunoglobulins/HRP
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pSMAD2 primary antibody

Cell Signalling Technology

produced in rabbit

Boston U.S.A

Total SMAD2/3 primary antibody

Cell Signalling Technology

produced in rabbit

2.1.10 Taqman® Primers/probes
Life Technologies™

Phosphoglycerate kinase 1
(PGK1) primer probe, VIC labelled

Life Technologies™

Gli1 primer probe,
FAM labelled. ID#: Hs01110766_m1

Life Technologies™

Gli2 primer probe,
FAM labelled. ID#: Hs01119974_m1

Life Technologies™

TGF-β1 primer probe,
FAM labelled. ID#: Hs00998129_m1

Life Technologies™

TGF-β2 primer probe,
FAM labelled. ID#: Hs00234244_m1

Life Technologies™

SMAD2 primer probe,
FAM labelled

Life Technologies™

SMAD3 primer probe,
FAM labelled

Life Technologies™

Ptch1 primer probe,
FAM labelled. ID#: Hs00970976_m1

2.1.11 Inhibitors/Small Interfering RNA (siRNA)
SB 431542, ALK5 inhibitor

Life Technologies™

SMAD2 siRNA

Life Technologies™

SMAD3 siRNA

Life Technologies™

Control siRNA

Life Technologies™

Control siRNA (FITC Conjugate)

Life Technologies™

2.1.12 Instruments and equipment
AGFA CP1000 X-ray processor

AGFA healthcare
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Scoresby, Victoria, Australia
Alphascreen proxiplate™ 384 plus

Perkin Elmer Life Sciences®

Black top seal adhesive films

Perkin Elmer Life Sciences®

CL-Xposure™ Film (18cm x 24cm)

Thermo Scientific

Corbett research Thermal Cycler

Fisher Biotec Wembley, WA, Australia

EnSpire® Multicode Plate Reader

Perkin Elmer Life Sciences®

Hypercassette™

Amersham Bioscience Australia

MicroAmp® Fast Optical

Life Technologies™

96 well plate {0.1 mL}
MicroAmp® Optical Adhesive Film

Life Technologies™

Moticam 3 CMOS Microscopy Camera

Perth Scientific Malaga, WA, Australia

Mr Frosty freezing container

Thermo Scientific

NanoDrop 2000 spectrophotometer

Thermo Scientific

Nikon® Coolpix 4500 camera

Nikon® Japan

Nikon® Eclipse Ti-S inverted microscope

Nikon® Kilda, Victoria, Australia

Olympus® 1x - 81® Inverted

Olympus® Morley, WA, Australia

Fluorescence microscope
StepOne Plus™ Real-time PCR system

Life Technologies™

Wallac Victor²V™ multilabel counter

Perkin Elmer Life Sciences®

Western blot electrophoresis

BIO-RAD

and transfer tanks

2.2 Buffers/Reagent Recipes
2.2.1 Glycine stripping buffer
Glycine

50 mM

SDS

35 mM

Tween-20®

1%

The components were dissolved in 1L ddH2O, the pH adjusted to 2.5 and stored at
4ºC.

2.2.2 Phosphate Buffered Saline (PBS) {20x}
Na₂HPO4

0.2 M
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NaCl

3M

KH₂PO4

30 mM

KCl

55 mM

The components were dissolved in ddH₂O, adjusted to pH 7.4 and made up to a final
volume of 1 L, sterilised and stored at room temperature. The solution was diluted
1:20 to 1x PBS in ddH₂O before use.

2.2.3 Sample Loading Buffer {4x}
Glycerol

40%

Tris/HCl pH 6.8

0.25 M

SDS

0.3 M

Bromophenol Blue

0.04%

β-mercaptoethanol

5%

The components were dissolved in 20 mL ddH₂O, aliquoted into eppendorf tubes
and froze at -20ºC until required.

2.2.4 SDS-PAGE Running Buffer {10x}
Tris-Base

0.25 M

Glycine

2M

SDS

35 mM

Components were dissolved content in 1 L ddH₂O, the pH checked to be around 8.0,
and then stored at room temperature before being diluted 1:10 in ddH₂O before use.

2.2.5 Stress Lysis Buffer (SLB)
HEPES

20 mM

MgCl₂

55 mM

EDTA

0.02 mM

β-glycerophosphate

30 mM

NaCl

0.1 M

Dilution was made up to a final volume of 500 mL in ddH₂O, adjusted to pH 7.7,
Aliquoted in 5mL sterile tubes and froze at -20ºC until required for use.
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2.2.6 SLB++
Triton®X-100

0.5%

NP40

1%

NaPyr

0.5 mM

Na₃VO4

0.2 mM

NaMolyb

1.0 mM

NaF

1.25 mM

Aprotinin

1 mM

Leupeptin

1 mM

PMSF

5 mM

DTT

5 mM

The components were added to 2 mL of SLB and used immediately.

2.2.7 Tris Buffered Saline (TBS) {10x}
Trizma Base

0.1 M

NaCl

1.5 M

The components were dissolved in 1 L ddH₂O, adjusted pH to 7.4 and stored at room
temperature. The solution was diluted 1:10 with ddH₂O before use.

2.2.8 TBS/Tween-20® (TBST) {1x}
Tween-20®

1%

1x TBS

1L

Tween-20® was dissolved in 1 L 1x TBS and thoroughly mixed then used
immediately.

2.2.9 Transfer Buffer {10x}
Tris-Base

0.25 M

Glycine

2M

SDS

3.5 M

Components were dissolved in 1 L ddH₂O, the pH checked to see it was in the range
of 8.0-8.3, stored at 4ºC and then diluted 1:10 in ddH₂O before use.
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2.2.10 Tris/HCL at pH 6.8/8.8
Tris/HCL

1.5 M

The powder was dissolved in ddH₂O, pH adjusted to either to 6.8 or 8.8 and then
made up to 50mL in ddH₂O before being stored at room temperature until required.

2.2.11 5% Milk + TBST
5% w/v Skim Milk Powder
1x TBS + 1% Tween 20®
Milk powder was dissolved in 1x TBST-T solution and used immediately.

2.2.12 10% w/v Ammonium Per sulphate (APS)
APS

1g

APS was dissolved APS in 10mL ddH₂O, aliquoted in 1.5mL eppendorf tubes and
stored at -20ºC until use.

2.2.13 Western Blot Gels
Stacking Gel

Running Gel

Acrylamide/Biscarylamide

6%

10%

SDS {20%}

0.5%

0.5%

Tris/HCl {1M}

0.125 M at pH 6.8

0.375 M at pH 8.8

APS

75 µL

75 µL

TEMED

10 µL

10 µL

The components of 6% stacking gel and 10% running gel were mixed in separate
falcon tubes and made up to 10 mL in ddH₂O.

2.3 Other Solutions
2.3.1 DNase 1
Qiagen® RNase free DNase set contains DNase 1 in a powder form, which was
diluted according to manufacturer’s directions in 550 µL of RNase free water.
Aliquoted in 0.6 mL eppendorf tubes and stored at -20ºC until use. A 10 µL solution
of DNase 1 was added to 70 µL of RDD buffer provided in the kit and used
immediately.
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Chapter 3
Methods
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3.1 Tissue Culture
3.1.1 Cell lines
Human mesothelioma cell lines used in this study were isolated from pleural
effusions (CRL2081, JU77, LO68, NO36 and VGE) (Manning, Whiteker, Murch,
Garlepp, Davis & Musk, 1991) or obtained from Plural Diseases Unit at Lung
Institute of Western Australia. An SV40 transformed non-tumorigenic normal human
mesothelial cell line (MeT-5A) originating from the pleural effusion of a noncancerous donor was also used (Ke at al., 1989). Primary mesothelial cells used in
this study were isolated and cultured by Ms. Kimberly Birnie. These cells originated
from pericardial fluids of patients undergoing heart surgery. Ethics approval for
collection of these cells was provided by the Sir Charles Gardner Hospital Human
Ethics Committee and RNA was isolated from these cells using the Qiagen® Reasy
Mini Kit (section 3.6.1).

3.1.2 Cell Culture conditions
All cells were cultured in 75 cm² tissue culture flasks containing growth medium
consisting of Dulbecco’s modified eagle’s medium (DMEM) with 10% foetal calf
serum (FCS), 4 mM L-glutamine, and either 100 U/mL penicillin and 100 µg/mL
Streptomycin or 5 mg/mL gentamycin. Cell cultures were switched to gentamycin in
the middle of the study due to issues with bacterial contamination. Cells were
incubated in 5% (v/v) CO₂ at 37ºC and passaged when confluent.

3.1.3 Cell Thawing and Freezing
Cell stocks were stored in liquid nitrogen (LN₂) and when required for culture, an
aliquot was removed and thawed at 37ºC in a water bath. Cells were then added to a
25 cm² flask containing 4 mL of growth medium. The next day the medium was
changed to 5 mL growth medium. Once the cells were confluent, they were passaged
and transferred to a 75 cm² flask.
For cell freezing, 1 x 106 cells were resuspended in 1 mL of freezing medium
(DMEM with 50% FCS and 10% DMSO). The cell suspension was added to a
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cryogenic vial and stored at -80ºC overnight in a Mr Frosty container. The following
day, the vial was transferred to LN₂.

3.1.4 Cell passage
Once the cells were confluent, the medium was aspirated from the flask and the cells
were washed twice with sterile 1x PBS to remove any remaining medium.
Thereafter, 1 mL of 0.25% trypsin/EDTA was added. Once the cells detached from
the surface of the flask, 1 mL of growth medium was added to neutralise the trypsin.
A single cell suspension was formed by adding 9 mL of growth medium to the flask
and pipetted up and down. Cells were then transferred to a sterile 15 mL falcon tube
and centrifuged at 1200 rpm for 5 min at room temperature. The supernatant was
aspirated and cells resuspended in fresh growth medium at appropriate
concentrations. Cell lines CRL2081, JU77 and LO68 were split at a ratio of 1:10,
NO36, VGE and MeT-5A were split at a ratio of 1:5. These cells were then made up
to 10 mL growth medium in a new 75 cm² flask.

3.1.5 Mycoplasma Testing
Cell cultures were assessed for Mycoplasma spp. infection every time a cell line was
removed from liquid Nitrogen (LN2). Mycoplasma are a group of micro-organisms
that may cause changes in cells by altering their cell metabolism, morphology, as
well as protein and RNA/DNA synthesis (Drexler & Uphoff, 2003). Following
trypsinisation and cell resuspension in growth medium during cell passaging, 1mL of
the cell suspension was added to a 1.5 mL microcentrifuge tube and centrifuged at
400 x g for 5 min. The supernatant was aspirated and 1mL of 0.9% saline (NaCl) was
added to the pellet and centrifuged at 400 x g for 5 min. The saline wash was
repeated twice. The pellet was left in the tube and sent to PathWest Laboratory
Medicine WA for mycoplasma testing. All the cell cultures used in this study were
negative for Mycoplasma spp.

3.1.6 Cell counting and seeding
Cells were counted in a haemocytometer to determine the number of cells available
for seeding. Following tryptinization and centrifugation, the cell pellet was re-
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suspended in 5 mL of fresh growth medium and a 10 µL aliquot of the cell
suspension was added to 10 µL of trypan blue and 10 µL loaded into a
haemocytometer. The cell concentration was calculated using the following equation:
Number of cells per mL = Total number of cells x 104
4

Based on this cell calculation, the correct concentration of cells were seeded into
assay plates. Cells were plated in growth medium to a total volume of 3 mL in 6 well
plates and 1 mL each in 12 well plates. Cells were then incubated in 5% (v/v) CO₂ at
37ºC. The number of cells plated in each type of plate type for different experiments
is shown in table 3.1.

Table 3.1: Cell densities seeded for each experiment and the type of culture
plate used.
Cell line

Experiment

Cell density

Type of plate

LO68, CRL2081,

Basal gene

0.75 x 105

12 well

JU77

expression

NO36

Basal gene

1.0 x 105

12 well

1.5 x 105

12 well

2.5 x 105

12 well

5.0 x 105

6 well

1.0 x 105

12 well

5.0 x 105

6 well

expression
MeT-5A, VGE

Basal gene
expression

LO68, CRL2081,

Gene expression

JU77, MeT-5A

with stimulation

LO68, MeT-5A

Protein expression
with stimulation

Met-5A, CRL

Gene expression

2081

with transfection

MeT-5A, CRL

Protein expression

2081

with transfection
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3.2 Basal gene expression
Following cell passage, cells were seeded in 12 well plates in triplicates at the
optimal seeding density for different cell lines as outlined in table 3.1. The correct
number of cells made up to 1mL per well in full growth medium were seeded in 12
well plates and incubated for 48 hr at 37ºC in 5% v/v CO₂. Following 48 hr
incubation, cells were harvested and mRNA levels for TGF-β1 and 2 and Gli1 and 2
determined according to section 3.6.
3.3 TGF-β stimulation
Following cell passage, cells were seeded in appropriate plates for mRNA expression
and protein experiments as outlined in table 3.1 and incubated overnight at 37ºC in
5% v/v CO₂. The next day the medium was aspirated and replaced with 1mL of
starvation medium (DMEM, 0.4% FCS, L-glutamine, Penicillin/streptomycin or
Gentamycin) in 12 well plates or 2mL in 6 well plates and incubated overnight. The
following day the starvation medium was aspirated and cells incubated with 5 ng/mL
TGF-β1 or TGF-β₂ was made up to 1 mL with starvation medium in each well for 12
well plates and up to 2 mL/well for 6 well plates. The control wells contained
2mg/mL BSA vehicle control in starvation medium. Cells were then incubated for 4
to 48 hr at 37ºC in 5% v/v CO₂ for mRNA expression and from 0-2 h for protein
measurement. At the appropriate time point cells were harvested for Gli1 and 2
mRNA and pSMAD2, total SMAD2/3 and α-tubulin protein expression analyses
according to section 3.6 and 3.7 respectively.
3.4 TGF-β receptor inhibitor studies
CRL 2081 and MeT-5A cells were used for all TGF-β receptor inhibition and Gli
studies. As per table 3.1, Met-5A and CRL 2081 cells were seeded in 12 well plates
at 2.5 x 105 per well and in 6 well plates at 5.0 x 105 for protein expression. The
CRL2081 cell line represents MM cell line and MeT-5A represents a non-malignant
mesothelial cell line. Following overnight incubation, the medium was replaced with
1mL and 2mL starvation medium in 12 well and 6 well plates respectively. The next
day cells were pre-treated with 20 µM of the TGF-β type 1 receptor (ALK5)
inhibitor, SB-431542. Cells were also treated with 5-10 µM of the Hh pathway
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inhibitor cyclopamine to determine if TGF-β-induced Gli expression occurs
independently of the classic Ptch/SMO-mediated hedgehog pathway. Control wells
were incubated with the same volume of 100% DMSO or ethanol as vehicle controls
for the ALK5 inhibitor or cyclopamine respectively. Cells were pre-treated for 1h
with negative inhibitors followed by stimulation with 5 ng/mL TGF-β₂ for 6 hr for
mRNA expression and up to 2 h for protein measurement and then lysed according to
section 3.6.1. The protocol for mRNA expression and protein detection was followed
as outlined in section 3.6 and 3.7 respectively.

3.5 Transfection of cells
Cells were seeded for mRNA or protein expression studies as shown in table 3.1.
After overnight culture, the medium was changed to DMEM with 10% FCS but no
antibiotics or L-glutamine for at least 45 minute prior to transfection, as outlined in
table 3.2.

Table 3.2: Volume of medium added to cells prior to transfection according to
plate type.
Type of plate

Volume of DMEM with 10% FCS, no
antibiotics or L-glutamine added

6 well

2800 µL

12 well

900 µL

Cell transfection was performed using two mixtures. The first transfection mixture
contained appropriate concentrations of SMAD2, SMAD3 or control siRNA made up
in DMEM (containing no FCS, L-glutamine or antibiotic). The volume of
transfection mixture per well depended on the type of plate used (outlined in table
3.4). The second transfection mixture contained Lipofectamine™ 2000 reagent also
made up in DMEM, and amounts of this mixture used determined by plate size are
shown in table 3.3. The first and second mixture were combined and incubated for 20
min at room temperature to allow complexing of the reagents. The total volume of
mixture as indicated in table 3.4 was then added drop wise to the appropriate well.
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The plates were gently rocked to combine the mixtures and returned to the incubator.
The siRNA to SMAD2, SMAD3 and control were initially transfected into cells at a
final concentration of 1 nM, 10 nM and 20 nM for optimisation experiments. 10 nM
concentration was subsequently chosen as the optimal concentration for SMAD2 and
SMAD3 inhibition studies.
Table 3.3: Volume of Lipofectamine™ 2000 made up in DMEM, and total
volume of the mixture per well according to plate type.
Plate

Lipofectamine™

DMEM/well (µL)

Total volume of
Lipofectamine™

2000/well (µL)

2000 +
DMEM/well (µL)
6 well

2

98

100

12 well

1
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Table 3.4: Volumes per well used for transfection of cells according to plate
type.
Plate

Volume of

Volume of

Total volume of

transfection

Lipofectamine™

complexes

mixture (µL)

2000 +

added/well (µL)

DMEM/well (µL)
6 well

100

100

200

12 well

50

50

100

At 24 hours following transfection, the medium was aspirated and 0.4% FCS
starvation medium was added to the cells. The following day, appropriate wells were
stimulated with TGF-β₂ and the cells lysed for Gli mRNA expression at 6 hr post
stimulation and phosphorylated and total SMAD2/3 protein measurement at 2 hr as
per section 3.6.1 and 3.7.1 respectively.
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3.6 mRNA expression analysis
Following treatments, cells were lysed and RNA isolated using the Qiagen® RNeasy
mini kit. The RNA was then converted to cDNA and analysed by Real-Time PCR.

3.6.1 Cell lysis, RNA isolation and quantification
The medium in 12 well plates was aspirated and 200 µL of the Lysis buffer from the
RNeasy mini kit was added to each well. A 1% v/v β-mercaptaethanol solution was
added to the kit lysis buffer immediately before use. All experiments were set up in
triplicate wells for each treatment and the lysates were combined into one
microcentrifuge tube. RNA was extracted according to the Qiagen® RNeasy mini kit
protocol with a minor modification to include DNAse 1 treatment. To degrade any
DNA contamination in the sample, 350 µL of wash buffer was added to spin
columns and centrifued at 12 000 x g for 15 sec. The waste was discarded and 80 µL
of RNase free DNAse 1 solution (section 2.3.1) was added to the spin columns and
left for 15 min at room temperature. A 350 µL aliquot of wash buffer was added to
the spin columns and centrifuged at 12 000 x g for 15 sec. The rest of the protocol
was performed according to the manufacturer’s instructions. RNA was eluted in 50
µL of RNase free water. The extracted RNA was quantified using a NanoDrop 2000
spectrophotometer and samples stored at -20ºC until use.

3.6.2 cDNA synthesis
cDNA was synthesised from RNA using the Qiagen® Omniscript Reverse
Transcriptase kit. The reaction mixture contained 1 µg of RNA, 1x RT buffer, dNTP
(500 µM), random hexamer primers (10 µM), RNase inhibitor (10 U), reverse
transcriptase (4 U) and RNase free water giving a total reaction volume of 20 µL. A
no template control was also included that contained everything except RNA, which
was replaced with RNase free water. The cDNA synthesis reaction was carried out at
37ºC for 60 min in the PCR thermocycler. Samples were stored at -20ºC until use.
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3.6.3 Real-Time PCR
Following cDNA synthesis, Real-Time PCR was carried out to determine the levels
of various mRNAs of interest in the human MM and control cell lines. The reactions
were performed in duplicate with a total volume of 10 µL per well in a 96 well
reaction plate. Each reaction contained 1uL of template cDNA, 1x TaqMan® gene
expression Master Mix, 1x TaqMan® probe and RNase free water. Controls included
the no template control from the cDNA synthesis, an RNA control (containing 2µL
of each RNA template used in the cDNA synthesis reaction) to detect any genomic
DNA contaminations and a water control to detect any real time PCR master mix
contamination. An adhesive optical film was used to cover the plate and the plate
centrifuged to collect the samples at the bottom of the wells. The samples were then
run on the StepOne Plus™ Real-time PCR system. The program consisted of 1 cycle
each of 50ºC for 2 min followed by 95ºC for 10 min followed by 40 cycles of 95ºC
for 15 sec and 60ºC for 1 min. The data was collected and stored during the run by
the StepOne software v2.1.

3.7 Protein analysis (Western blot)
3.7.1 Protein extraction
Cells seeded in 6 well plates as previously outlined in table 3.1 were used for protein
analysis. The medium was aspirated from wells and cells washed twice with ice cold
1x PBS. SLB++ buffer (section 2.2.6), 220 µL for 100% confluent cells and 110 µL
for 70-90 confluent cells was then added to the wells. The cells were scraped from
the plate and the suspension transferred in to a microcentrifuge tube. The tube was
then vortexed and incubated on ice for 10 min followed by 10 min centrifugation at
13 000 x g at 4ºC. The supernatant was transferred to a new microcentrifuge tube and
stored at -20ºC until use.

3.7.2 Protein quantification (Coomassie plus Bradford Assay)
The Coomassie plus Bradford assay was used to quantify protein samples. Different
concentrations of BSA were prepared from 2 mg/ml stock BSA and deionised water
to use as a standard curve. Concentrations of the BSA ranged from 0.05 mg/ml to
0.75 mg/ml. Protein samples were diluted 1:10 and 1:20 in deionised water and 10
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µL of that was plated in duplicates in a 96 well plate followed by 200 µL of
Coomassie plus reagent. Solutions were mixed by tapping the plate then incubated at
room temperature for 5 min before reading at 595 nm on the Wallac Victor
Multilable Counter.

3.7.3 Sample preparation
The concentration of protein in each sample was calculated from the Coomassie plus
Bradford assay. Samples were thawed at room temperature and the appropriate
volume of sample required for 10-20 µg of protein was made up to 16 µL with
deionised water and added to 4 µL of loading buffer, giving a total of 20 µL. The
tubes were then heated to 95ºC for 10 min and centrifuged briefly. Samples were
then loaded onto the polyacrylamide gel for electrophoresis.

3.7.4 Gel electrophoresis
The polyacrylamide gel consisted of a 10% running gel and 6% stacking gel. The
protein samples were loaded into the wells. A 5 µL Precision Plus protein™ dual
coloured standard was also loaded. The running tank was then filled with 1x SDSPAGE running buffer and run at 180V for approximately 45 min.

3.7.5 Electrophoretic protein transfer
Once the gel electrophoresis was complete, the PVDF (soaked in methanol for 10
min) or nitrocellulose transfer membrane, sponges and filter paper, were all soaked
in 1x transfer buffer for approximately 10 min. A cassette was prepared and the gel
and membrane were sandwiched between sponge and filter paper with sponge first
then filter papers, gel, membrane, filter papers, and another sponge. These were all
sandwiched together after ensuring no air bubbles formed between the gel and the
membrane. The cassette and an ice block were placed in the transfer tank and the
tank filled with cold 1x transfer buffer (4ºC). The proteins were transferred at 100v
for 1.5 hr at room temperature.
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3.7.6 Protein detection
After protein transfer was complete, the cassette was dissembled and the membrane
blocked for 1 hr at room temperature in TBST with 5% skim milk powder (chapter 2,
Section 2.2.11) to block non-specific binding. The membrane was then washed 4
times with 1 x TBST (section 2.2.8) for 5 min each before being incubated with the
primary antibody at 4ºC overnight. Primary antibodies used in this study were diluted
in 5% skim milk TBST as shown in table 3.5. Following overnight incubation, the
membrane was washed 4 times in TBST for 5 min each at room temperature and then
incubated for 1.5 hr in secondary antibody diluted in 1% skim milk TBST as
described in table 3.5. Membranes were washed 4 times with 1 x TBST for 5 min
each prior to the addition of Immobilon Western HRP Substrate. Protein bands were
detected at different exposures with CL-Xposure™ Film using the AGFA developer
in a CP1000 X-ray processor.

Table 3.5: Dilutions of primary and secondary antibody used for western blot
analysis
Primary antibody Dilution used

HRP conjugated Dilution used
secondary
antibody

α-tubulin

1:15,000

Anti-mouse

1:50,000

pSMAD2

1:3,000

Anti-rabbit

1:25,000

pSMAD3

1:3,000

Anti-rabbit

1:25,000

Total SMAD2/3

1:3,000

Anti-rabbit

1:25,000

3.7.7 Membrane Stripping
Membranes were stripped with two 15 min washes in glycine stripping buffer. The
membranes were then washed 4 times in 1 x TBST for 5 min each before being
blocked for 1 hr in 5% skim milk TBST. The membrane was then incubated in
primary antibody overnight at 4ºC and the western blot process continued as
described in section 3.7.6.
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3.7.8 Western blot analysis optimisation
Following analysis of baseline TGF-β1/2 and Gli1/2 in MM and control cells, 3 MM
and control MeT-5A cell lines were selected for TGF-β1/2 stimulation studies to
examine Gli expression. Activity of TGF-β can be measured by examining the
protein expression of its downstream signalling molecules such as SMAD2/3 and
specifically the phosphorylation of SMAD2 and SMAD3. For optimisation of
pSMAD2, pSMAD3 and total SMAD2/3, antibodies for western blot analysis were
used at various concentrations: primary (1:1,000 to 1:4,000) and secondary (1:1,000
to 1:5000).

During the optimisation process, it was discovered that the PVDF transfer membrane
produced excessive background and band fuzziness (figure 3.1 A), therefore I
decided to use nitrocellulose membranes for all further experiments. Total SMAD2/3
had to be optimised so that there was a clear separation of the two protein bands. The
SDS-page gel was initially run at 100V for 2 hr to produce band separation for
accurate quantitation (figure 3.1 B), but in the later experiments the gel was run at
180V for 45 min which produced better band separation (figure 3.1 C).

After several optimisation runs it was determined that the best western blot
conditions were to run the SDS-page gel at 180V for 45 min and the protein transfer
onto a nitrocellulose membrane and probed with the optimised concentrations of
primary and secondary antibodies.

A

C

B

Figure 3.1 Optimisation of total SMAD2/3 antibody with different western blot
conditions. (A) SDS page gel run at 100V for 1.5 hr and proteins transferred onto a
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PVDF membrane showing fuzziness of the bands and high background. (B) SDS
page gel run at 100V for 1.5 hr and proteins transferred onto a nitrocellulose
membrane produced cleaner bands. (C) SDS page gel run at 180V for 45 min and
proteins transferred onto a nitrocellulose membrane produced clean and crisp bands.

3.8 Surefire protein assay
3.8.1 Protein quantitation and sample preparation
Cells were seeded into 6 well plates at optimal seeding densities as outlined in table
3.1. After overnight incubation at 37ºC, the medium was aspirated from each well
and 2 mL of starvation medium added. After 16-24 hr incubation the wells were
stimulated with 5 ng/µL TGF-β₂ and protein lysed using 1 x Lysis buffer supplied by
the Alphascreen® Surefire® Assay kit. The samples were then incubated on ice for
10 min before being centrifuged at 12 000 x g for 3 min to pellet insoluble material.
The supernatants were transferred to a new microcentrifuge tube and stored at -20ºC
until use. To ensure equal loading of protein, the concentration was quantified using
a Bradford assay as described in section 3.7.2. A 1µg aliquot of protein for each
sample was made up to 4 µL in ddH₂O water and added to a Proxiplate 384 well plus
plate.

3.8.2 Alphascreen® Surefire protein assay
After the addition of 4 µL of the prepared protein lysates (section 3.7.1) to the
Proxiplate 384 Plus plate, 5 µL of acceptor mix was added to the wells. The acceptor
mix contained acceptor beads diluted 1:50 in activation buffer and reaction buffer
mix (the activation buffer diluted 1:5 in reaction buffer). The plate was then sealed
with a top seal black adhesive cover, wrapped in aluminium foil and incubated for 2
hr at room temperature in a dark environment. The plate was then unsealed and 2 µL
of donor mix containing the donor beads diluted 1:20 in dilution buffer was added to
the wells. The plate was again resealed with the black adhesive seal and wrapped in
aluminium foil and incubated at room temperature in a dark environment for 2 hr or
overnight for better protein detection. The plate was unsealed and fluorescence in
each sample quantified using the EnSpire plate reader.
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3.9 Flow Cytometry
3.9.1 Cell setup and harvest
Cells were transfected according to section 3.5 with fluorescent labelled siRNA.
From this point the cells were kept in the dark where possible. After 24 hr of
incubation, the medium was aspirated and the cells washed twice with 1xPBS. A 50
µL aliquot of trypsin/EDTA was then added to each well followed by 200 µL of 1 x
PBS. Once the cells detached from the surface of the well, 50 µL of growth medium
was added to each well to neutralise the trypsin/EDTA. The suspension was then
added to 3 mL sterile glass tubes and centrifuged at 1200 for 5 min at room
temperature. The supernatant was then discarded, the pellet resuspended in 1 mL of 1
x PBS and centrifuged again at 1200 for 5 min. The supernatant was then removed,
the pellet resuspended in 500 µL 1 x PBS and the cells immediately examined using
the Olympus® IX-81® inverted fluorescence microscope.

3.10 Statistical Analysis
Microsoft Excel and GraphPad Prism 5.0 were used to analyse data. Data is
presented as mean ± standard error of the mean (SEM) with three or more replicates.
Statistical analysis was performed by a student’s unpaired t-test or one way analysis
of variance for multiple comparisons using one way ANOVA. A p value of equal to
or less than 0.05 was considered to be significant. Data with only two replicates are
presented as mean.
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Chapter 4
Results
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4.1 Cell Morphology
MM cell lines used in this study were morphologically consistent with those
previously published (Manning et al., 1991) (figure 4.1). At confluence the
CRL2081 and LO68 cells expressed a spindled shaped morphology (figure 4.1 A
and C), whereas JU77, NO36 and VGE cells had a cobblestone, epithelial-like
morphology at confluence (figure 4.1 B, E and F). The control human transformed
mesothelial cell line MeT-5A, was also epithelial-like when confluent but had a more
fibroblastic morphology when sub-confluent, which is consistent with their original
morphology at isolation (Ke et al., 1989) (figure 4.1 D).

A

CRL2081

B

JU77

0.2 mm

C

E

LO68
LO68

D

MeT-5A
MeT-5A

F

VGEVGE

NO36

Figure 4.1: Morphology of confluent cell lines. (A) CRL2081 (B) JU77 (C) LO68
(D) MeT-5A (E) NO36 and (F) VGE cells. Bar = 0.2 mm.
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4.2 Baseline levels of TGF-β1/2 and Gli1/2 in MM and control cells.
Baseline levels of TGF-β1/2 and Gli1/2 mRNA were measured in 5 MM cell lines
and control MeT-5A and primary mesothelial cells by real-time PCR. These cells
were the once available at the laboratory and thus screened for the baseline levels.
Determining the basal gene expression levels of TGF-β and Gli in these cells will
allow comparisons to be made between normal and malignant cells and provide a
reference point for differences in gene expression for subsequent experiments.

4.2.1 Baseline levels of TGF-β1 and TGF-β2 mRNA in MM and control cells.
TGF-β plays an important role in modulating the growth and immune function of
many types of cancer and is also produced by several different cancer cell types
including MM (Fitzpatrick et al., 1994). In this study the baseline levels of TGF-β1
and TGF-β2 mRNA in 5 MM and MeT-5A cell lines were compared to control
normal mesothelial cells. RNA isolated from primary mesothelial cells was kindly
provided by Ms. Kimberly Birnie in our laboratory. Human PGK-1 was used as an
endogenous control. The level of TGF-β1 mRNA varied between different MM cell
lines. MeT-5A, LO68 and JU77 cells had high levels of TGF-β1 mRNA (p-value of
0.0209, 0.0004 and 0.0018 respectively), while VGE (p-value of 0.0485) and NO36
had lower TGF-β1 mRNA levels than control mesothelial cells but the difference
wasn’t significant (figure 4.2).

The level of TGF-β2 mRNA was also measured in all cell lines and control cells. The
levels were lower in MeT-5A and MM cells compared with control mesothelial cells
(figure 4.3), but the differences were not significant in other cell lines except
CRL2081 (p-value of 0.0100).
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Figure 4.2: Baseline TGF-β1 mRNA levels in MM and control cells. TGF-β1
mRNA levels were quantified by real time PCR and the results normalised to PGK-1.
MM and MeT-5A cell lines (dark grey bars) were compared to primary mesothelial
cells (light grey bar). Data represent the mean of three experiments. Error bars =
SEM (standard error of mean). *= p ≤ 0.05. **= p ≤ 0.01. ***= p ≤ 0.001.
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Figure 4.3: Baseline TGF-β2 mRNA levels in MM and control cells. TGF-β2
mRNA levels were quantified by real time PCR and the results normalised to PGK-1.
MM and MeT-5A cell lines (dark grey bars). Primary mesothelial cells (light grey
bar). Data represent the mean of three experiments. Error bars = SEM. *= p ≤ 0.05.

4.2.2 Baseline Gli1 and Gli2 mRNA levels in MM and control cells.
The effector molecules of the Hh signalling pathway are the Gli transcription factors
(Forbes et al., 1996). This study measured Gli1 and Gli2 mRNA levels in MM, MeT5A and primary mesothelial cells. Gli1 expression was higher in MeT-5A and 4 out
of 5 MM cell lines compared with primary mesothelial cells (figure 4.4), although
the difference was only significant in three MM cell lines, LO68, CRL2081 and
NO36 (p-value of 0.0022, 0.0085 and 0.0002 respectively). JU77 cells had
significantly lower Gli1 mRNA levels compared to primary cells (p-value of 0.0101).
Similarly, Gli2 expression was higher in MeT-5A and 3 out of 5 MM cell lines
compared to primary mesothelial cells, however only LO68 was significantly
different (p-value of 0.0128) (figure 4.5).
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Figure 4.4: Baseline Gli1 mRNA levels in MM and control cells. Gli1 mRNA
levels were quantified by real time PCR and the results normalised to PGK-1. MM
and MeT-5A cell lines (green bars) were compared to primary mesothelial cells
(white bar). Data represent the mean of three experiments. Error bars = SEM. *= p ≤
0.05. **= p ≤ 0.01. ***= p ≤ 0.001.

65

Gli2 mRNA expression

0.05

*

0.04
0.03
0.02
0.01

36
O
N

L2
C

R

VG
E

08
1

77
JU

68
LO

5A
eT
M

Pr

im

ar
y

0.00

Cell lines
Figure 4.5: Baseline Gli2 mRNA levels in MM and control cells. Gli2 mRNA
levels were quantified by real time PCR and the results normalised to PGK-1. The
MM and MeT-5A cell lines (maroon bars) were compared to primary mesothelial
cells (white bar). Data represent the mean of three experiments. Error bars = SEM.
*= p ≤ 0.05.
4.3 Confirmation of TGF-β1 and TGF-β2 activity.
TGF-β is known to induce phosphorylation of SMAD2 and SMAD3 and TGF-β1 is
known to stimulate the production of many extracellular matrix (ECM) proteins
including collagen type-1 (Ignotz & Massague, 1986). Therefore, I wanted to see if
my preparation of recombinant TGF-β1/2 induced phosphorylation of SMAD2 and
stimulated collagen type-1α1 mRNA production in one of my MM cell lines JU77.
Based on previous studies in my laboratory and from published data, I expected
pSMAD2 increase over time with TGF-β stimulation and maximal collagen mRNA
expression at 24 hr, therefore this confirmation experiments were done on the cell
line previously shown to be inducing this.
4.3.1 TGF-β signalling is mediated by the SMAD2/3 pathway in MM cells.
The SMAD proteins transmit signals from the TGF-β receptors at the cell membrane
to the nucleus and initiating transcription of TGF-β target genes (Massague et al.,

66

2000). Based on previous findings and antibody database, the cells were incubated
with recombinant TGF-β2 and protein isolated at 0, 1/2, 1 and 2hrs. JU77 cells were
treated with 5 ng/mL TGF-β1 for up to 2 hr and results compared with untreated
control. TGF-β1 induced an increase in pSMAD2 over time as expected confirming
activity of the TGF-β1 preparation I was using (figure 4.6 A). MM and MeT-5A cells
were incubated with recombinant TGF-β2 for 30, 60 and 120 min and pSMAD2 and
total SMAD2/3 protein examined by western blot. All three cell lines showed
significant induction of pSMAD2 in response to TGF-β2 stimulation within 2 hr of
stimulation (figure 4.8 A, B, C and D).
4.3.2 TGF-β induces human collagen type-1α1 mRNA expression in MM and
control cells.
For collagen mRNA expression, cells were stimulated with TGF-β1 or TGF-β2 for 6,
24 and 48 hr. Using JU77 cells, TGF-β1 significantly upregulated collagen type-1α1
mRNA at 24 hr compared with unstimulated control (p-value of 0.0168) (figure 4.6
B), similar observations were made with JU77 cells stimulated with TGF-β2 (figure
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4.7). These results were consistent with previous findings in my laboratory.
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Figure 4.6: TGF-β1 induces the expression of human collagen type-1α1 mRNA
and pSMAD2 in JU77 cells. (A) pSMAD2 and total SMAD2/3 protein expression
were determined by western blot following 30 min 1h and 2hr TGF-β1 stimulation.
Data represents one experiment. (B) Collagen type-1α1 mRNA levels were
quantified by real time PCR and the results normalised to PGK-1. Data is presented
as fold change above control at three different time points. Red bars show expression
at 6 hr, green bars show expression at 24 hr and blue bars show expression at 48 hr.
Data represents the mean of three experiments. Error bars = SEM. Significance
compared to respective control: *= p ≤ 0.05.
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Figure 4.8: TGF-β2 induces phosphorylation of SMAD2 in MM and MeT-5A
cells. Total SMAD2/3 and pSMAD2 was examined by western blot 2 h after TGF-β2
stimulation. White bars show unstimulated control. Pink bars show TGF-β2
stimulated cells. (A) Representative western blot for pSMAD2 and total SMAD2/3.
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CRL2081 (C) LO68 and (D) MeT-5A. Data represent the mean of three experiments.
Error bars = SEM. Significance compared to control: *= p ≤ 0.05. **= p ≤ 0.01.
***= p ≤ 0.001.

4.4 The effect of TGF-β1 and TGF-β2 on Gli1 and Gli2 mRNA levels in MM and
control cells.
Recent studies have shown an interaction between Hh and TGF-β signalling
pathways in a variety of cell types (Dennler et al., 2007). This interaction occurs
downstream of SMO and targets Gli2 in some normal and malignant cell types
(Alexaki et al., 2010). Gli1 expression is subsequently activated in a Gli2 dependent
manner (Dennler et al., 2007). Therefore in this study the effect of TGF-β1 and TGFβ2 on Gli1 and Gli2 mRNA levels were examined in MM and control MeT-5A cells
at various times. LO68 cells were selected as they showed high expression of Gli1
and Gli2 mRNA expression, whereas JU77 cells showed low levels and CRl2081
cells displayed variable levels. The earlier time point (4-6hr) was set to examine
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early Gli2 expression while the later time points (24 and 48hr) for the subsequent
Gli1 expression.

4.4.1 Effect of TGF-β1 on Gli1 and Gli2 MM and control cells.
TGF-β1 and TGF-β2 are both important for MM growth (Kuwahara et al., 2001),
therefore in this study the effect of both TGF-β isoforms on Gli1 and Gli2 mRNA
levels in MM and control cells were examined.

Figure 4.9 and 4.10 show relative Gli1 and Gli2 mRNA levels after TGF-β1
stimulation in MM and MeT-5A cells at 6, 24 and 48 hr. TGF-β1 did not increase
Gli1 or Gli2 mRNA levels in any of the cell lines when compared with unstimulated
controls. In fact there was a significant decrease in Gli1 mRNA levels at 24 h
compared to control in LO68 cells (p value of 0.0134) but this was due to high levels
of Gli1 mRNA in the 24 hr control.
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Figure 4.9: TGF-β1 does not stimulate an increase in Gli1 mRNA levels in MM
and control cells. Gli1 mRNA levels were quantified by real time PCR and the
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Figure 4.10: TGF-β1 does not increase Gli2 mRNA levels in MM and control
cells. Gli2 mRNA levels were quantified by real time PCR and the results normalised
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4.4.2 Effect of TGF-β2 on Gli1 and Gli2 expression in MM and control cells.
The effect of TGF-β2 on Gli1 and Gli2 mRNA was examined in three MM and
control MeT-5A cell lines at 4, 6, 24 and 48 hr. TGF-β2 had no effect on Gli1 mRNA
expression compared to unstimulated controls in all cell lines tested (figure 4.11).
Interestingly, Gli1 mRNA levels were high in the control samples at 24 hr consistent
with the observations made with TGF-β1 stimulations. TGF-β2 caused a significant
down regulation of Gli1 mRNA levels in MeT-5A cells at 24 hr compared to its
unstimulated control (p-value of 0.0242).

TGF-β2 stimulated a significant increase in Gli2 mRNA levels at 4-6 hr in all of the
cell lines, including control MeT-5A cells (figure 4.12). A 2.5 and 3 fold increase in
Gli2 mRNA expression was observed in CRL2081 and MeT-5A cell lines (p-value
of 0.02 and 0.0039 respectively) at 6 h and approximately a 2 fold change in LO68
and JU77 cells at 4h (p-value of 0.0179 and 0.0367 respectively). CRL2081 and
control MeT-5A cell lines were subsequently selected for further studies.
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4.4.3 Effect of TGF-β2 on Ptch1 mRNA expression in CRL2081 and control
cells.
Several studies have shown Ptch1 to be a target gene for Gli1 (Cigna et al., 2012),
and Gli2 (Kim et al., 2007: Regl et al., 2004: Lipinski et al., 2008). In this study I
examined the effect of TGF-β2 on Ptch1 mRNA levels in CRL2081 and MeT-5A
cells 24 hr and 48 hr post treatment by real-time PCR. CRL2082 cells were selected
as they showed greater response with TGF-β2 for Gli2 mRNA expression, and the
MeT-5A cells served as control. Ptch1 mRNA levels did not change at 24 h but
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increased at 48h compared to control in both the cell lines (figure 4.13), but was only
significant in MeT-5A cells (p-value of 0.0127).
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Figure 4.13: Ptch1 expression after TGF-β2 treatment in CRL2081 and MeT-5A
cells. Ptch1 mRNA levels were measured by real time PCR and the results
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normalised to PGK-1. White bars show unstimulated cells. Blue bars show TGF-β2
stimulated cells. Data is expressed as mRNA expression for (A) CRL2081 and (B)
MeT-5A cells. Bars represent the mean of three experiments. Error bars = SEM. *= p
≤ 0.05.

CRL2081 and MeT-5A cell lines were selected for further inhibition studies. As
CRL2081 had highest Gli2 activation after TGF-β2 stimulation and MeT-5A served
as a non-malignant control cell line.

4.5 Effect of blocking TGF-β receptor on Gli2 expression.
MM cells produce TGF-β (Marzo et al., 1997). Therefore to further explore the
potential interaction between TGF-β and Hh pathways in MM cells, I examined the
effect of blocking TGF-β2 signalling on Gli2 mRNA levels. ALK5 receptor inhibitor
SB-431542 compound was used to block the TGFβRI/ALK5 receptor which
mediates TGF-β signalling in a wide range of cell types (Ebner et al., 1993).
Blocking TGFβRI/ALK5 should inhibit TGF-β2 mediated phosphorylation of
SMAD2/3, preventing transcription of TGF-β2 target genes including Gli2 (Inman et
al., 2002).

4.5.1 SB-431542 reduced phospho-SMAD2 protein in CRL2081 and MeT-5A
cells.
To confirm that inhibiting the TGF-β2 receptor complex abrogated downstream
signalling, I examined pSMAD2 by western blot analysis. Incubation of CRL2081
and MeT-5A cells with TGF-β2 lead to robust induction of pSMAD2 which was
inhibited when cells were pretreated with SB-431542 prior to TGF-β2 exposure.
Figure 4.14 A shows a western blot of CRL2081 and MeT-5A cells treated with SB431542 and DMSO control in the presence or absence of TGF-β2 and assessed for
pSMAD2, total SMAD2/3 and α-tubulin. As shown is figure 4.14 B and C there was
a 4.2 fold inhibition of pSMAD2 in CRL2081 cells pretreated with SB-431542 then
treated with TGF-β2 and a 15.3 fold decrease in MeT-5A cells.
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Figure 4.14: SB-431542 inhibits pSMAD2 protein expression in CRL2081 and
MeT-5A cells. pSMAD2 and total SMAD2/3 levels were assessed by western blot.
α-tubulin was used as a lane loading control. White bars show treatment in the
absence of TGF-β2. Orange bars show TGF-β2 stimulated cells. (A) Western blots
showing pSMAD2, total SMAD2/3 and α-tubulin expression for CRL2081 and MeT5A cells. Densitometric analysis showing pSMAD2 normalised against total
SMAD2/3 for (B) CRL2081 and (C) MeT-5A. Each bar represents the mean of two
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experiments. Abbreviations: ALK5 inh (ALK5 inhibitor-SB431542), TB2 (TGFβ2).

4.5.2 SB-431542 blocks TGF-β2-mediated Gli2 mRNA expression in CRL2081
and MeT-5A cell lines.
Initial studies optimised SB-431542 inhibition of TGF-β signalling by treating cells
with different concentrations of the inhibitor. The optimal concentration was 20 µM
and therefore this concentration was used in all subsequent studies (figure 4.15).
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Figure 4.15: Optimisation of SB-431542 treatment in CRL2081 cells. Gli2
mRNA was quantified by real-time PCR and the results normalised to PGK-1. White
bars show controls and red bars show different concentration of SB-431542 treated
cells. Data is presented as mRNA expression. Each bar represents one experiment.
Abbreviations: ALK5 inhibitor – SB431542 (SB).
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CRL2081 and MeT-5A cells were pretreated with SB-431542 or its vehicle control
for 1h then stimulated with TGF-β2. After 6hr the cells were harvested and Gli2
mRNA expression was analysed. Consistent with previous findings both CRL2081
and MeT-5A cells showed significant Gli2 induction by TGF-β2 compared to its
DMSO or untreated controls (p-value of 0.0254, 0.0328 and 0.0269 respectively).
Gli2 mRNA expression levels in cells treated with SB-431542 in presence or absence
of TGF-β2 was compared to cells treated with vehicle control stimulated with TGFβ2. SB-431542 significantly suppressed TGF-β2 induced Gli2 mRNA expression in
both cell lines (figure 4.16) (p-value of 0.0458 and 0.0248 in CRL2081 cells and
0.0010 and 0.0107 in MeT-5A cells).
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Figure 4.16: SB-431542 abrogates TGF-β2-induced Gli2 mRNA expression. Gli2
mRNA was quantified by real time PCR and the results normalised to PGK-1. White
bars show different treatments and red bars show cells with different treatments and
stimulated with TGF-β2. Data is presented as relative expression for (A) CRL2081
and (B) MeT-5A cells. Data represents the mean of three experiments. Error bars =
SEM. Significance compared to TGF-β2 unstimulated controls: *= p ≤ 0.05.
Significance compared to cells treated with DMSO + TGF-β2: ^= p ≤ 0.05. ^ ^ ^= p ≤
0.001.

4.6 Effect of blocking the SMAD2/3 pathway on TGF-β2 induced Gli2
expression.
To determine if the SMAD2/3 pathway is involved in TGF-β2 mediated Gli2
expression in MeT-5A and CRL2081 cells, SMAD signalling was blocked using
siRNA to SMAD2/3 genes. The concentration of siRNA was optimised to
successfully knock down SMAD2 and SMAD3 mRNA and protein in MeT-5A cells.
Cells were then transfected with siRNA against SMAD2 or SMAD3 and treated with
TGF-β2. Gli2 mRNA expression was evaluated by real-time PCR and pSMAD2 and
total SMAD2/3 protein expression was assessed by western blot.
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4.6.1 Optimisation of siRNA concentrations to block SMAD2 and SMAD3
siRNA concentrations were optimised in MeT-5A cells. Cells were transfected with
1, 10 or 20 nM siRNA against SMAD2 or SMAD3. The SMAD2 and SMAD3
mRNA and pSMAD2 and total SMAD2/3 protein were measured after 48 hr. As
shown in figure 4.17. Transfection of 10nM SMAD2 or SMAD3 siRNA resulted in a
3.2 fold reduction in SMAD2 mRNA and a 4.3 fold reduction in SMAD3
respectively relative to controls. At 20nM siRNA there was non-specific suppression
of SMAD targets. Therefore 10nM siRNA was used for all subsequent experiments.

The specificity of the siRNA knockdown was further investigated by analysing
SMAD2/3 protein expression by western blot. Figure 4.18 A shows western blot of
MeT-5A cells treated with 10 and 20nM siRNA to SMAD2 and SMAD3 and
assessed for pSMAD2, total SMAD2/3 and α-tubulin protein expression. Treatment
of cells with 10nM SMAD2 siRNA knocked down pSMAD2 and total SMAD2
proteins by 50% compared with control (figure 4.18 B and C), and SMAD3 siRNA
knocked down approximately 40% total SMAD3 protein (figure 4.18 D). Consistent
with mRNA data, treatment of MeT-5A cells with 20nM siRNA led to a non-specific
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Figure 4.18: SMAD2 and SMAD3 siRNA suppressed pSMAD2 and total

SMAD2/3 protein expression in MeT-5A cells. pSMAD2 and total SMAD2/3
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levels were examined by western blot analysis. α-tubulin was used as an endogenous
and lane loading control. White bars show untransfected or control siRNA
transfected cells. Purple and green bars show siRNA transfections. (A) Western blot
showing pSMAD2, total SMAD2/3 and α-tubulin expression inMeT-5A cells.
Densitometric analysis showing pSMAD2 (B), total SMAD2 (C) and total SMAD3
(D) expression was normalised against α-tubulin. Each bar represents the mean of
two experiments.

4.6.2 Validation of SMAD2/3 mRNA expression knockdown.
The effect of SMAD2 and SMAD3 siRNA on SMAD2 and SMAD3 mRNA levels
was examined in CRL2081 and MeT-5A cells. Transfection with SMAD2 and
SMAD3 siRNA reduced the basal levels of SMAD2 and SMAD3 respectively
compared to control siRNA (figure 4.19).

SMAD2 siRNA reduced SMAD2 mRNA levels by 60% in CRL2081 cells (figure
4.19 A), and by 50% in MeT-5A cells (figure 4.19 B) (p-value of 0.0409 and 0.0060
respectively). SMAD3 siRNA reduced SMAD3 mRNA levels by 45% in CRL2081
cells (figure 4.19 C) and approximately 40% in MeT-5A cells (figure 4.19 D) (pvalue of 0.0384 and 0.0321 respectively). Similar effects were observed when
combining siRNAs to SMAD2/3. In CRL2081 cells SMAD2/3 siRNA reduced
SMAD2 mRNA levels by 50% and by 60% in MeT-5A cells (figure 4.18 A and B)
(p-value of 0.0500 and 0.0076 respectively). There was approximately 30%
inhibition in SMAD3 mRNA levels in CRL2081 cells and 60% in MeT-5A cells with
combined SMAD2/3 siRNA (figure 4.19 C and D).
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Figure 4.19: SMAD2 and SMAD3 siRNA supresses SMAD2/3 mRNA in
CRL2081 and MeT-5A cells. Cells were transfected with siRNA against SMAD2 or
SMAD3 (coloured bars) or controls (white bars). SMAD2 and SMAD3 mRNA
levels were quantified by real time PCR and the results normalised to PGK-1. Data is
presented as mRNA expression of SMAD2 in (A) CRL2081 and (B) MeT-5A and
SMAD3 in (C) CRL2081 and (D) MeT-5A. Data represent the mean of four
experiments. Error bars = SEM. Significance compared control siRNA transfected
cells: *= p ≤ 0.05. Abbreviations: Control siRNA (Cont siRNA), SMAD2 siRNA (si
SD2), SMAD3 siRNA (si SD3), SMAD2 and SMAD3 siRNA (si SD 2/3).
4.6.3: Validation of SMAD2/3 protein expression knockdown.
To confirm that siRNA to SMAD2 and SMAD3 inhibits SMAD proteins, CRL2081
and MeT-5A cells transfected with SMAD2 and SMAD3 siRNA and total and
pSMAD2 and pSMAD3 proteins analysed by western blot. These cells were also
stimulated with TGF-β2 after SMAD2 and SMAD3 siRNA transfections to examine
reduction in pSMAD2 and pSMAD3 proteins compared to TGF-β2 induced levels.
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Staining for α-tubulin was used as an endogenous control and lane loading control.
Phosphorylated SMAD2 and SMAD3 were reduced when cells were transfected with
siRNA to SMAD2 and SMAD3 respectively (figure 4.20 A and 4.21 A). SMAD
siRNAs also knocked down TGF-β2 mediated pSMAD2 and total SMAD2/3
respectively. However the knock down was only around 40-50% for phosphorylated
SMAD2 (figure 4.20 B and 4.21 B) and 25% for SMAD3 (figure 4.20 C and 4.21
C) compared with controls for both cell lines. In both cell lines, partial knockdown
of total SMAD2 and SMAD3 protein was also observed with respective siRNAs
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Figure 4.20: SMAD2 and SMAD3 siRNA transfections shows a trend towards
reduced pSMAD2/3 and total SMAD2/3 protein in CRL2081 cells. Coloured bars
show transfections followed by TGF-β2 stimulation. White bars show treatment in
the absence of TGF-β2. (A) Western blots for pSMAD2, total SMAD2/3 and αtubulin loading control. Densitometric analysis showing pSMAD2 (B), pSMAD3
(C), total SMAD2 (D) and total SMAD3 (E) normalised to α-tubulin. Data represent
mean of two experiments.
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Figure 4.21: SMAD2 and SMAD3 siRNA transfections shows a trend towards
reduced pSMAD2/3 and total SMAD2/3 protein in MeT-5A cells. Coloured bars
show transfections followed by TGF-β2 stimulation. White bars show controls in the
absence of TGF-β2. (A) Western blots for pSMAD2, total SMAD2/3 and α-tubulin
loading control. Densitometric analysis showing pSMAD2 (B), pSMAD3 (C), total
SMAD2 (D) and total SMAD3 (E) normalised to α-tubulin. Data represent mean of
two experiments. Abbreviations: No siRNA (No si), Control siRNA (Cont si).

4.6.4 Gli2 induction by TGF-β2 is SMAD2/3 dependent.
To determine if TGF-β2-induced Gli2 expression is SMAD2/3 dependent, CRL2081
and MeT-5A cells were transfected with 10nM siRNA to SMAD2, SMAD3 or
control siRNA treated with TGF-β2 and Gli2 mRNA levels measured. Following
TGF-β2 treatment, there was strong induction of Gli2 mRNA in both cell lines. This
induction was reduced when the cells were transfected with SMAD2 or SMAD3
siRNA (figure TGF4.22). SMAD2 and SMAD3 siRNA showed greatest inhibition
of Gli2 mRNA expression in CRL2081 cells (p-value of 0.0093 and 0.0044
respectively) (figure 4.22 A). Although there was a trend for a decrease in Gli2
levels in MeT5A cells transfected with SMAD2 and SMAD3 siRNA (figure 4.22 B).
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Figure 4.22: SMAD2 and SMAD3 siRNA suppress TGF-β2-mediated Gli2
mRNA expression in CRL2081 and shows a trend towards a decrease in MeT5A cells. Gli2 mRNA levels were quantified by real time PCR and the results
normalised to PGK-1. Cells transfected with siRNA targeting SMAD2, SMAD3 or
control siRNA were treated with TGF-β2 (red bars) or left untreated (white bars) and
Gli2 mRNA levels measured. Data is presented as mRNA expression for (A)
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CRL2081 and (B) MeT-5A cells. Data represents the mean of four experiments.
Error bars = SEM. Significance compared to TGF-β2 unstimulated controls: *= p ≤
0.05. Significance compared control siRNA transfected and TGF-β2 treated cells: ^=
p ≤ 0.05. ^ ^= p ≤ 0.01.

4.6.5 Transfection efficiency of siRNA in CRL2081 and MeT-5A cells.
As the knockdown effects of siRNA to SMAD2 and SMAD3 were only moderate, I
wanted to measure the transfection efficiency in the cell lines. The SMAD2/3 siRNA
used in the study did not have a label that could be used to assess transfection
efficiency. Therefore I transfected cells with control siRNA containing a fluorescein
conjugate (FITC) designed to measure transfection efficiency. FITC is a light
reactive dye that can be quantified by FACS analysis. Similar to other siRNA
transfection experiments, 10nM FITC labelled control siRNA was transfected into
cells and efficiency assessed 24 hr after transfection. The cell population was gated
based on the dimensions and complexity of the cells analysed (figure 4.23 A for
CRL2081 and figure 4.24 A for MeT-5A cells). The cell population was separated
into FITC negative and FITC positive cells using untransfected cells as negative
controls (figure 4.23 B and C for CRL2081 and figure 4.24 B and C for MeT-5A
cells). Transfection was only about 6% in CRL2081 and 27% in MeT-5A cells
(figure 4.23 D and 4.24 D).
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Figure 4.23: Transfection efficiency of FITC labelled control siRNA in
CRL2081 cells. The percentage of cells expressing FITC label was determined. (A)
representative scatter plot showing side scatter height (SCC-H) verses forward
scatter height (FSC-H) and gating the cell population and creating a (B) histogram of
FITC fluorescence intensity showing an untransfected cell population and the gating
for FITC positive cells and (C) histogram of FITC fluorescence intensity showing
transfected cell population and gating for FITC positive cells. (D) Percentage of
FITC positive cells. Data is the mean of three wells in one experiment. Error bars =
SEM.
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Figure 4.24: Transfection efficiency of FITC labelled control siRNA in MeT-5A
cells. The percentage of cells expressing FITC fluorescence intensity was
determined. (A) Representative dot points plotting side scatter height (SCC-H) verses
forward scatter height (FSC-H) and gating the cell population and creating a (B)
histogram of FITC fluorescence intensity showing an untransfected cell population
and the gating for FITC positive cells and (C) histogram of FITC fluorescence
intensity showing transfected cell population and gating for FITC positive cells. (D)
Percentage of FITC positive cells. Data is the mean of three wells in one experiment.
Error bars = SEM.
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4.7 Effect of cyclopamine on TGF-β2 mediated Gli2 expression in cell lines.
Studies in different tours have shown that induction of Gli by TGF-β is independent
of Hh signalling (through Ptch/Smo axis) (Dennler et al., 2007). To determine if
TGF-β2-induced Gli2 is also independent of Hh signalling in MM, cells were treated
with TGF-β2 in presence or absence of cyclopamine (a SMO inhibitor) and Gli2
mRNA levels measured. If TGF-β2-induced Gli2 upregulation is independent of Hh
signalling, cyclopamine will have no effect on induction of Gli2.

4.7.1 Effect of cyclopamine on TGF-β2 mediated Gli2 mRNA expression
The effect of blocking Hh signalling with cyclopamine on TGF-β2-mediated Gli2
mRNA expression was examined in MM and control cells. As shown in figure 4.25,
samples pretreated with vehicle control then stimulated with TGF-β2 had an
unexpected reduction in Gli2 mRNA levels in both MeT-5A and CRL2081 cells.
Although cyclopamine treated cells had reduced Gli2 mRNA, no conclusion could be
drawn from this experiment. Further optimisation studies are required to eliminate
the effect of the control before the effect of blocking the Hh pathway on TGF-β2induced Gli2 mRNA can be adequately assessed.

99

A
Gli2 mRNA expression

0.15

0.10

0.05

U

nt
re
at
ed
Ve
hi
cl
e
5
M
C
yc
lo
5
M
Ve
hi
cl
e
10
M
C
yc
lo
10
M

0.00

Treatment

B
Gli2 relative expression

0.20
0.15
0.10
0.05

M
10

M
C

yc
lo

10

5
M

Ve
hi
cl
e

C

yc
lo

5
M

Ve
hi
cl
e

0
M

0.00

Treatment
Figure 4.25: Cyclopamine and vehicle control reduced TGF-β2 induced Gli2
expression in CRL2081 and MeT-5A cells. CRL2081 and MeT-5A cells were
treated with cyclopamine and controls and then stimulated with TGF-β2. Gli2 mRNA
was quantified by real time PCR and the results normalised to PGK-1. White bars
show treated cells in the absence of TGF-β2. Red bars show treated stimulated with
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TGF-β2. Data is presented as mRNA expression (A) MeT-5A and (B) CRL2081
cells. Data represents mean of two experiments in MeT-5A and one experiment in
CRL2081 cells. Abbreviations: Cyclopamine (Cyclo).

4.7.2 Effect of cyclopamine on Ptch1 expression in MeT-5A cells.
As cyclopamine and the vehicle control affected Gli2 levels, I examined their effect
on another target gene Ptch1. MeT-5A cells were selected as these served as the
control cells, and I wanted to investigate the effect of cyclopamine in these cells
before progressing to MM cells. MeT-5A cells were pretreated with cyclopamine or
vehicle control for 1h before incubation with TGF-β2. Ptch1 mRNA expression
levels were then measured after 6 hr. Ptch1 levels were reduced by 5 µM but not the
10 µM cyclopamine compared with the vehicle treated controls but this effect was
restored in the presence of TGF-β2 (figure 4.26). Further experiments need to be
performed to confirm this observation.
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Figure 4.26: Treatment with cyclopamine down regulated Ptch1 expression in
MeT-5A cells. MeT-5A cells were treated with cyclopamine or vehicle control,
stimulated with TGF-β2 and Ptch1 mRNA levels quantified by real time PCR. The
results were normalised to PGK-1. White bars show treated cells without TGF-β2
stimulation. . Blue bars show treated cells with TGF-β2 stimulation. Data represents
the mean of two repeat experiments.

4.8 Quantitative measurement of pSMAD2 protein using alphascreeen®
Surefire® technology.
The Alphascreen® Surefire® technology by Perkin and Elmer is a recently
developed method used to quantify signalling proteins within cell lysates. This
technique requires less protein and is fully quantitative rather than the semiquantitative western blots technique. This method was used to generate a quantitative
measure of pSMAD2 protein levels expressed in cell lysates and to support the
western blot data. The pSMAD2 units obtained from the assay were divided by those
of GAPDH or Histone endogenous control to obtain a ratio.
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4.8.1 Quantitative analysis of pSMAD2 using Alphascreen analysis.
To optimise the assay for measuring pSMAD2 levels using Alphascreen technology,
the MeT-5A cells were stimulated with TGF-β2 and lysed at different time points. I
wanted to firstly investigate the effect in MeT-5A cells for the optimization
experiments. GAPDH protein expression was used as an endogenous control to
normalize levels of pSMAD2 protein. Results show a trend towards an increase in
the expression of pSMAD2 in TGF-β2 stimulated cells over time compared with
unstimulated control (figure 4.27), but the increase was only observed at 2 hr (1.8
fold increase p-value 0.0230). This increase was less than the results obtained by
western blot analysis (4.5 fold change in pSMAD2 at 2 hr compared to unstimulated
control) (figure 4.8).
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Figure 4.27: pSMAD2 protein levels normalised to GAPDH in MeT-5A cells
using Alphascreen technology. pSMAD2 protein expression following TGF-β2
stimulation normalised to GAPDH detected using the Surefire® assay. White bar
shows unstimulated control. Green bars show TGF-β2 stimulated cells. Data
represent the mean of three experiments. Error bars = SEM. Significance compared
to untreated control: *= p ≤ 0.05.
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4.8.2 pSMAD2 levels normalised to Histone in MeT-5A cells.
For MM cells GAPDH may not be the most suitable endogenous control as previous
unpublished data in our laboratory showed that GAPDH levels can change upon
different treatments. Therefore, data was normalised to Histone levels and expressed
as a ratio. There was no significant change in the level of pSMAD2 in MeT-5A cells
at any of the time points examined compared with unstimulated control (figure
4.28). In contrast, western blot analysis revealed an increase in pSMAD2 over time
(figure 4.8). Further examination of the result showed that there was a high variation
in Histone expression, which skewed the data.
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Figure 4.28: pSMAD2 protein levels normalised to Histone in MeT-5A cells
using Alphascreen technology. pSMAD2 protein expression following TGF-β2
stimulation normalised to Histone. White bar shows unstimulated control. Green bars
show TGF-β2 stimulated cells. Data represent the mean of three experiments. Error
bars = SEM.
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Chapter 5
Discussion
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Malignant mesothelioma MM is a fatal cancer of the mesothelium (Spugnini et al.,
2006) associated with poor prognosis due to difficulties in diagnosis and the lack of
treatment options currently available (Chen & Pace., 2012). Therefore, novel
targeted therapies are required (Kao et al., 2010). Recent studies have focused on the
role of aberrantly expressed developmental signalling pathways in the pathogenesis
of several cancers (Dennler et al., 2007: Cigna et al., 2012). Two of these pathways
are the Hh and TGF-β signalling pathways. There is increasing evidence that these
pathways work together to promote tumour growth. Some studies have identified
TGF-β as a potent inducer of the primary Hh effector molecule and transcription
factor, Gli (Alexaki et al., 2004; Dennler et al., 2007; Javelaud et al., 2012; Mohseny
et al., 2012). The current study aimed to investigate the interaction of these two
pathways at the level of Gli, in MM. Identifying new pathways that regulate tumour
cell growth may lead to the development of novel therapies.

5.1 TGF-β expression in MM cells
TGF-β is a multifunctional cytokine and has a defined, yet complex role in mediating
or regulating a series of stochastic events that occur in cancers. (Sporn et al., 1986).
There are three mammalian isoforms of TGF-β (Massague, 1998). This study
examined basal mRNA expression levels of the most abundant forms of TGF-β,
TGF-β1 and TGF-β2 in MM cells. Previous studies have demonstrated substantial
production of TGF-β isoforms in human and mouse MM cell lines (Gerwin et al.,
1987; Lauber et al., 1992; Fitzpatrick et al., 1994). The effect of blocking
endogenous TGF-β on MM cell and tumour growth using antisense oligonucleotides
to TGF-β1 and TGF-β2 showed significant biological effects on MM cell function and
blocking TGF-β2 inhibited tumour growth in vivo (Fitzpatrick et al., 1994; Marzo et
al., 1997). Therefore it is clear that TGF-β is an important molecule in MM growth
but how it mediates it’s effects are not clear. To investigate the interaction between
TGF-β and Hh signalling I first needed to determine how much of each TGF-β
isoform was produced in the cells I used in my study.
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Basal levels of TGF-β1 mRNA was generally expressed higher in control MeT-5A
cells but had variable expression across the MM cell lines studied compared to
primary mesothelial cells. Basal levels of TGF-β2 mRNA was generally expressed
lower in MM and MeT-5A cells compared to primary mesothelial cells. However,
this study only measured mRNA levels and future studies should also measure
protein. A previous study examined TGF-β protein in MM tumour tissue by
immunohistochemistry, and showed differential localisations of TGF-β isoforms,
where TGF-β1 was shown to be localised more in the stroma than in cells and TGFβ2 more in MM tumour cells then in the stroma (Jigardar et al., 1997). Although I
saw more TGF-β1 than TGF-β2 mRNA in the cells this may not reflect protein levels.
Also, as cells secrete TGF-β in the latent form, immunolocalisation studies would
only measure total TGF-β and not the amount of active TGF-β present. Therefore a
more specific type of assay is required which would measure active TGF-β isoforms
such as enzyme linked immunosorbent assay (ELISA). The assay detects latent TGFβ, which can then be activated with acids to measure the amount of active TGF-β
isoform protein present in cell supernatants. In this study, I performed initial
optimisation experiments using ELISA to measure active and latent TGF-β1 and
TGF-β2 in MM cells (results not included). However, the latent level was below the
level of detection. Therefore, this technique needs further optimisation, such as
concentrating the cell culture supernatants using ultrafiltration approaches. Despite
only measuring mRNA levels of TGF-β1 and TGF-β2 in this study, the findings show
that both isoforms are produced by MM cells with possibly more TGF-β1 related to
malignancy that TGF-β2. However, the importance of TGF-β2 cannot be overlooked
given that TGF-β2 antisense oligonucleotides blocked MM tumour growth in vivo
(Marzo et al., 1997). Knowing the basal mRNA levels of TGF-β for each cell line
also provided a reference point for subsequent experiments.

5.2 Gli expression in MM cells
I also examined the mRNA expression of the Hh signalling pathway effector
molecules Gli1 and Gli2. Baseline mRNA levels of both Gli1 and Gli2 was variable
across the MM cell lines and MeT-5A cells had higher Gli1 and Gli2 levels
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compared to primary mesothelial cells. Although there was variable expression of
Gli across cell lines, most cells produced Gli mRNA, supporting reports from other
studies and suggesting a role for Gli and the Hh pathway in MM growth (Shi et al.,
2012; Li et al., 2013). Expression of Gli3 transcription factor mRNA was not
measured in this study as it is known to be a transcriptional repressor (Matice &
Joyne, 1999), and other studies have shown a minimal effect of TGF-β on Gli3
expression (Dennler et al., 2007; Cigna et al., 2012).

5.3 TGF-β signals through the SMAD pathway in MM
Among the immediate transduction pathways activated by TGF-β, the canonical
signalling pathway is the SMAD cascade (Massague et al., 2005). SMADs are
carriers of TGF-β receptor signals into the nucleus and phosphorylation of SMAD2
and SMAD3 by the TGF-β receptor complex is a critical step in TGF-β ligand
signalling and transcriptional regulation (Ebner et al., 1993). Binding of TGF-β
ligand to cell specific receptors activates and phosphorylates TβRI, and this then
phosphorylates SMAD2 and SMAD3 which form a complex with SMAD4. The
resulting complex moves to the nucleus and transcription of the target genes is
achieved (Padgett, 1999).
I firstly wanted to confirm activity of the human recombinant TGF-β1 and TGF-β2
preparations used in this study. This was confirmed by phosphorylation of SMAD2
proteins and its known downstream target gene human collagen type-1α1. TGF-β1
increased pSMAD2 over time in JU77 cells and also stimulated collagen type-1α1
mRNA maximally at 24 hr, consistent with previous findings in our laboratory.
However due to the nature of the total SMAD2/3 antibody used in this project, it was
difficult to obtain a band each of SMAD2 and SMAD3 proteins by western blotting
and therefore the quantitation of SMAD2 proteins with imageJ was difficult to
perform. Similar to the TGF-β1 isoform, TGF-β2 also induced an increase in
pSMAD2 levels as well as collagen production in MM cells, confirming the activity
of both TGF-β preparations. To my knowledge, this is also the first time the effect of
TGF-β2 on pSMAD2 has been examined in MM cells. Interestingly, the maximal
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fold increase in collagen mRNA induced by TGF-β2 was higher than for TGF-β1. For
JU77 cells, TGF-β1 stimulated a 2.8 fold increase in collagen mRNA at 24 hr
compared with a 14 fold increase after TGF-β2 stimulation. This suggests differential
effects of the two TGF-β isoforms in these cells.
Although western blot analysis showed that TGF-β increased pSMAD2, this
technique is semi-quantitative, and estimates of protein are prone to factors that may
alter the final outcomes (Gassman et al., 2009). As a result, better and more
quantitative measurements of protein changes are required. Recently, a newer
approach called the Alphacreen® Surefire® assay has been developed to detect these
proteins in a much more efficient, accurate and timely manner (Hurt & Titus, 2010).
This assay is a proximity based sandwich immunoassay which uses a combination of
antibodies, donor beads and acceptor beads, which bind with the target protein
creating protein complexes that release quantifiable light directly correlating to the
amount of target protein in that sample (Hurt & Titus, 2010). Several studies have
successfully optimised and utilised this assay to quantify protein expression in vitro
(Crouch et al., 2010). Results obtained to date in this study did not reflect the western
blot data and so most likely needs to be further optimised. However, due to time
constraints I was unable to fully optimise this technique.

5.4 Effect of TGF-β1/2 on Gli1/2 mRNA levels in MM cells.
The effect of TGF-β1 and TGF-β2 on Gli mRNA expression was then examined in
MM and control cell lines. TGF-β1 has previously been shown to stimulate an
increase in Gli2 which in turn upregulates Gli1 in a Gli2-dependent manner (Dennler
et al., 2007; Cigna et al., 2012). In glioblastoma, pancreatic adenocarcinoma and
lung fibroblast cell lines, a rapid induction of Gli2 in response to TGF-β1 was
observed, peaking between 2-8 hr and levels remaining above basal expression up to
24 hr, whereas delayed induction of Gli1 was observed between 16-24 hr (Dennler et
al., 2007; Cigna et al., 2012). Interestingly, TGF-β1 had no effect on either Gli2 or
Gli1 levels in the 4 MM and control MeT-5A cell lines examined. As MM cells also
produce TGF-β2 and blocking TGF-β2 inhibits MM tumour growth (Marzo et al,
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1997), I decided to examine the effect of TGF-β2 on Gli expression. TGF-β2 induced
Gli2 mRNA between 4-6hr in all MM cell lines and control MeT-5A cells in a
similar fashion to previous reports for TGF-β1, but interestingly had no effect on Gli1
mRNA expression up to 48 hr after treatment.
Previous studies have shown that TGF-β isoforms have a similar structure but serve
different biological functions in different cell types in vitro and in vivo (Millan et al.,
1991). For example, TGF-β1 gene knockdown mice experience defective
haematopoiesis and endothelial differentiation, while TGF-β2 null mice exhibit
cardiac, lung, ear and urogenital defects and TGF-β3 gene ablation mice results in
delayed pulmonary development (Dunker & Kreiglstein, 2001; Sanford et al., 1997).
This illustrates diverse biological roles of these isoforms which can influence cell
growth and differentiation in different cell types in a positive or negative manner
(Sporn et al., 1986). Thus, despite most studies having shown that TGF-β1 induces
Gli expression in various cancers, this study showed that TGF-β1 was ineffective in
inducing Gli in MM cells but TGF-β2 could, highlighting the differential role of the
two isoforms in respect to Gli activation.
This differential response may be because it has been reported that TGF-β2 has a
different mode of receptor activation (Rotzer et al., 2001). As previously described,
signalling via TGF-β1 is initiated when TGF-β1 binds to TGFβRII, and this recruits
the binding and phosphorylation of TGFβR1 (Wrana et al., 1994). Activated TGFβRI
phosphorylates its cytoplasmic effectors SMAD2/3, which phosphorylates and forms
a complex with SMAD4, translocates to the nucleus and initiates transcription of
target genes (Massague et al., 1999). In contrast, TGFβRII has a low intrinsic affinity
for the TGF-β2 isoform (Lin et al., 1995). TGFβRIII or betaglycan acts as a coreceptor and is required for the responsiveness of TGF-β2, TGFβIII binds to TGF-β2
and presents it to TGFβRII, and this has been described in different cell types
(Sankar et al., 1995; Brown et al., 1999). However it is incompletely understood why
direct binding of TGF-β1 to TGFβRII does not have the same effect (Rotzer et al.,
2001). Therefore, Brown et al. (1999) proposed that TGF-β2 alters the activity and
composition of TGFβRII-TGFβRI complex in order to activate downstream
signalling molecules, resulting in specific TGF-β2 effects, and that TGFβRIII has a
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preferential affinity for the TGF-β2 isoform. Supporting this, an earlier study by
Mitchell at al. (1992) demonstrated that compared to mesenchymal enriched primary
placental cells, trophoblast enriched primary placental cell cultures were more
responsive to TGF-β2 than TGF-β1 due to the presence of an active form of
betaglycan receptor at the cell surface. Eickelberg and colleagues, (2001) examined
the function of betaglycan in renal epithelial LLC cells and L6 myoblast cells and
observed that expression of betaglycan in LLC cells inhibited TGF-β1 signalling,
measured by collagen expression and phosphorylation of downstream SMAD2/3
proteins. In comparison, the expression in L6 cells enhanced TGF-β1 signalling. The
expression of betaglycan in LLC cells prevented association between TGFβRI and
TGFβRII. Therefore it is possible that in MM cells, betaglycan inhibits TGF-β1
signalling but supports TGF-β2 signalling by acting as a co-receptor. However, this
needs to be confirmed by further studies such as measuring the expression of
TGFβRIII in these cells.
It was also interesting to note that TGF-β2 induced maximum Gli2 expression in all
cells lines studied between 4 and 6 hr but the levels then reduced back to basal levels
at 24 and post TGF-β2 stimulation. These observations are not consistent with the
findings by Dennler et al. (2007). As previously described, they observed rapid and
persistent Gli2 induction by TGF-β1, peaking between 2-8 hr and remaining at levels
higher than their basal expression up to 24 hr. This could possibly be an effect of a
negative regulator of TGF-β signalling, SMAD7 forming stable complexes with
active TGF-β receptor complexes and interrupting the phosphorylation of SMAD2/3,
blocking transcription of target genes (Zhu, Chen & Chen, 2011). Therefore, this
observation in the current study could mean that although TGF-β2 induces an effect
on Gli2 expression, this effect could be short lived and may only be functionally
important in that time frame. Examination of Gli2 target genes at later times might
suggest functional importance.
Another interesting observation following TGF-β1 and TGF-β2 treatment in MM
cells is that Gli1 levels were upregulated in the control 24 hr sample in all cell lines
examined. A possible reason for this response could be initiation of cell survival
mechanisms through the Hh signalling pathway. Cells are cultured in 0.4% FCS
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supplemented medium for 24 hr before and after TGF-β stimulation. Therefore, cells
are starved of serum and hence growth nutrients for an extended period of time. This
stress response may in itself stimulate Gli1 expression. The Hh pathway is required
for growth and survival of tumour cells (Bar et al., 2007). Previous studies showed
that Hh pathway activation, as evidenced by elevated expression of its target gene
Gli1, leads to increased transcription of anti-apoptotic molecules such as Bcl-2 in
medullablastoma (Bar et al., 2007). Other studies have shown that expression of Bcl2 is predominantly regulated by Gli2 instead of Gli1, such as in plasmacytoma
tumour cells (Regl et al., 2004). In this study, induction of Gli expression at 24 hr in
controls may be a defence mechanism but ultimately masks any increased expression
of Gli1 at 24 hr in response to TGF-β. This mechanism is worth exploring.
The functional significance of TGF-β2-induced Gli2 induction can be assessed by
measuring downstream targets for Gli2. Previous studies have shown Ptch1 to be a
target gene for Gli1 (Cigna et al., 2012), while others have shown that it is a Gli2
target (Kim et al., 2007; Regl et al., 2004; Lipinski et al., 2008). Therefore, to
confirm functional significance of Gli2 activation, the regulation of Ptch1 mRNA
expression levels were examined in TGF-β2 stimulated CRL2081 and MeT-5A cell
lines. Ptch1 was upregulated at 48 hr post TGF-β2 stimulation compared to its
unstimulated control in both cell lines, however only MeT-5A showed significance.
Although this may be due to the direct effect of Gli2 upregulation, the timing of
expression of Ptch1 is not consistent with previous reports (Cigna et al., 2012). As
Gli2 is induced at earlier time points in response to TGF-β2, I expected upregulation
of Ptch1 at around 24 hr rather than 48 hr if it was a Gli2 target gene in these cells.
Therefore it is possible that Gli1 was upregulated in response to TGF-β2 at 24 hr and
hence the delay in upregulation of Ptch1. Clearly this is impossible to confirm when
control levels of Gli1 were also upregulated after 24 hr with TGF-β2 treatment, but
this requires further investigation.
In this study I measured the effect of TGF-β isoforms on Gli mRNA levels rather
than protein. This was because of difficulty measuring Gli isoforms using currently
available antibodies for western blot analysis. An alternative approach would have
been to use a Gli1 or Gli2 reporter assay following TGF-β1/2 treatment. A reporter
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construct (such as Luciferase) is attached to the gene of interest (Gli1 or Gli2) to
create gene fusion. This construct is integrated into cellular genomic DNA.
Following appropriate stimulation there is activation of transcription of the reporter
gene which releases the reporter protein. In the case of luciferase, this is measured by
a luminometer, and the intensity of the signal is a direct reflection of the level of
activity of the gene of interest (Smale, 20010).
I then wanted to examine the mechanisms regulating TGF-β2-mediated Gli2
upregulation. To do this I chose two cell lines; MM cell line CRL2081 and control
MeT-5A (Reddel et al, 1989). Both cell lines were induced by TGF-β2 to up-regulate
Gli2 mRNA expression. Ideally normal mesothelial cells would have been used as
controls for all experiments but cultures of normal mesothelial cells were not
available during the study. Although TGF-β2 induced Gli2 activation, it was unclear
if TGF-β2 acted directly on Gli2 or was dependent on the classical Hh Ptch/SMO
axis. Dennler et al. (2007) showed that cyclopamine abrogated shh induced Gli2
expression but has no effect on TGF-β1 mediated Gli2 expression.
However, Cigna et al. (2012) showed that in human lung fibroblasts (HLFs), TGF-β
induced mRNA and protein expression of α-SMA (Smooth muscle actin), collagen
and fibronectin. Blocking Hh signalling using cyclopamine inhibited the expression
of these proteins showing the requirement of Hh signalling in TGF-β-mediated
expression of certain proteins in these cells. Similarly, Yoo et al. (2008) showed that
Shh promotes motility and invasiveness of gastric cancer cells through TGF-βmediated activation of the ALK5-SMAD3 pathway.

To examine the role of the classic Hh signalling pathway in MM, cells were treated
with TGF-β2 in the presence or absence of the SMO inhibitor cyclopamine.
Cyclopamine is a steroidal alkaloid isolated from corn lily, and blocks Hh pathway
signalling by blocking the Ptch/SMO axis and influencing the function of SMO (Yao
et al., 2011).

(Ingham & McMahon, 2001). If TGF-β2 was acting through

Ptch/SMO, then cyclopamine would block the actions of TGF-β2. If not, then
cyclopamine would have no effect. Studies have analysed the optimal concentration
of cyclopamine for its ability to block cellular response and thus, 5 and 10µM
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concentrations were used in this study (Chen et al., 2002; Yao et al., 2011).
Unfortunately, although I saw a reduction in Gli2 mRNA levels following TGF-β2
treatment in the presence of cyclopamine, there was an equal reduction in vehicle
(ethanol) controls. Therefore, no conclusions could be drawn from this study. Due to
the unexpected effect of the vehicle control, further optimisation of this experiment
needs to be performed, possibly using a different vehicle control such as DMSO or
water, depending on the solubility properties of the cyclopamine preparation.
Unfortunately there was not enough time available for me to perform these
optimisation experiments in this study.
An alternative to measuring Gli2 levels in cyclopamine and TGF-β2 treated
mesothelial cells is to measure an alternative downstream target gene for Gli such as
Ptch. As expected, cyclopamine blocked Ptch1 mRNA expression in Met-5A cells,
but the levels were restored in the presence of TGF-β2. This suggests that TGF-β2
induces Ptch1 independent of Ptch/SMO-mediated signalling in MeT-5A cells.
However, this experiment was only performed once and only in MeT-5A cells.
Therefore these findings need to be confirmed and the effect on MM cells examined.

5.5 SB-431542 inhibits TGF-β2-induced Gli2 expression in MM cells.
I then wanted to determine if TGF-β2 was stimulating Gli2 mRNA upregulation
through the classic TGF-β signalling receptor TβRI/ALK5 via the SMAD signalling
pathway. The TGF-β ligand brings together type 1 and type II receptor complexes.
The type II receptor phosphorylates and activates the type I receptor (ALK5)
(Moustakas et al., 1993) and the signals are transduced to the nucleus primarily
through activation of the SMAD2/3 complex (Ebner et al., 1993). To assess the role
of the ALK5 receptor in TGF-β2-mediated Gli2 expression, I measured TGF-β2induced Gli2 mRNA expression after blocking TGF-β2 signalling using the ALK5
inhibitor SB-431542. This is a potent inhibitor of the ALK5 receptor that acts as a
competitive ATP binding site kinase inhibitor, and has been shown to inhibit the in
vitro phosphorylation of SMAD2 and SMAD3 (Inham et al., 2002). To examine the
effectiveness of this inhibitor, cells were pretreated with SB-431542 followed by
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TGF-β2 stimulation. TGF-β2 alone increased phosphorylation of SMAD2 in both
CRl2081 and MeT-5A cells. However, in the presence of SB431542, pSMAD2
induction by TGF-β2 was prevented. Consequently, TGF-β2-induced Gli2 was also
inhibited by SB-431542. Therefore it was concluded that TGF-β2 acts through the
ALK5 receptor to induce Gli2 mRNA expression.

5.6 TGF-β2-induced Gli2 is mediated throught the SMAD2/3 signalling cascade.
I then wanted to determine if TGF-β2-induced Gli2 was mediated through SMAD2/3
signalling. Western blot data clearly showed that TGF-β2 induced pSMAD2/3 in MM
and MeT-5A cells. However, TGF-β can also signal through other pathways such as
MAPK and PI3K. The approach I used was to block SMAD2 and SMAD3 using
specific siRNA and measure its effect on TGF-β2-mediated Gli2 expression.
I first tested the transfection efficiency of this approach. Unfortunately, the siRNA
available to SMAD2 and SMAD3 were not tagged with a reporter molecule and so I
could not work out the efficiency directly from my SMAD transfection studies.
Therefore, I used an FITC labelled scrambled siRNA. Both cell lines demonstrated a
low percentage of cells carrying the label, with only 6% efficiency in CRL2081 cells
and 25% in MeT-5A. The experiment was performed using live cell harvest for
FACS analysis which would compromise the mortality of cells and the transfection
efficiency. Therefore, this low transfection efficiency could be due to technical issues
when performing the experiment such as extended spinning time, or delay during cell
harvest. If I had more time I would optimize the technique with other harvesting and
cell fixing techniques before FACS analysis to avoid technical issues and get a better
readout.

Despite the relatively low transfection efficiency, I tried to obtain effective mRNA
and protein knockdown of pSMAD2 and total SMAD2/3 using SMAD2 and SMAD3
siRNA at a range of concentrations. The 1 nM concentration had limited effect,
whereas I got significant knockdown at 10 and 20 nM siRNA although at 20 nM
some of the effects may have been non-specific. Previous studies have shown that
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high concentrations of siRNA can have off-target effects and relatively low
concentrations (e.g 1 nM) are sufficient to silence the intended target (Caffrey et al.,
2011). The 10 nM siRNAs led to efficient knockdown at the mRNA and protein
level, and therefore this concentration was used for subsequent experiments. siRNA
to SMAD2 and SMAD3, individually and combined, effectively knocked down
SMAD2 and SMAD3 mRNA and protein phosphorylation in both CRL2081 and
MeT-5A cells in the presence or absence of TGF-β2, with the greatest effect when the
SMAD2 and SMAD3 siRNA were combined. However, as the transfection
efficiency in CRL2081 cells was so low, it is unclear if this result was real or non
specific. Further optimisation studies are needed to confirm siRNA results in
CRL2081 cells. Analysis of Gli2 mRNA levels following TGF-β2 stimulation in cells
transfected with SMAD2 and SMAD3 siRNA, clearly showed suppression of TGFβ2-mediated Gli2 mRNA, confirming the role of the SMAD pathway. These results
are consistent with the findings by Dennler et al. (2007) where they showed that
SMAD3 siRNA markedly impaired TGF-β-induced Gli2 mRNA expression in
fibroblasts and keratinocytes.

5.7 Summary and Conclusions
MM remains a disease with a dismal outcome. Hh and TGF-β signalling pathways
are involved in numerous overlapping processes during development and recent
studies have discovered this interaction may be important in the pathogenesis of
some cancers (Perrot et al., 2013; Javelaud et al., 2012; Dennler et al., 2007).
Therefore the role of this interaction in diagnosis, prognosis and treatment options in
MM have to be investigated. This study aimed to determine whether this pathway
interaction occurs in MM, particularly if TGF-β induces the Gli transcription factors.
TGF-β1/2 isoforms and Gli1/2 are variably expressed in MM cell lines. TGF-β1 had
no effect on Gli1 or Gli2 expression. However, TGF-β2 induced Gli2 but not Gli1
mRNA expression. Both TGF-β1 and TGF-β2 signals through the canonical SMAD
signalling pathway and blocking TGF-β2 signalling at the TβRI receptor level
inhibited TGF-β2 mediated Gli2 mRNA expression and pSMAD2 protein expression.
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Knocking down SMAD2/3 using siRNA also inhibited increased TGF-β2-mediated
Gli2 mRNA levels, confirming the role of the SMAD2/3 signalling pathway in TGFβ2-mediated Gli2 upregulation. However, it is yet to be determined if TGF-β2mediated Gli2 activation is independent of Hh signalling, and if this interaction plays
a functional role in MM tumour growth.

From the results of this study, it can be concluded that TGF-β2 is a potent inducer of
Gli2 and mediates its effects through the SMAD2/3 signalling pathway. Although
further studies are required to determine that targeting TGF-β/Gli interaction may
provide therapeutic benefits for MM patients.

5.8 Future directions
This study has confirmed the interaction of TGF-β with Hh signalling pathway
effector molecules Gli, but further studies are required to delineate the signalling
mechanisms and elucidate the biological significance of this interaction. The current
study was limited by only examining this interaction at the level of Gli mRNA.
Therefore to further address the interaction of Hh and TGF-β signalling pathways,
the study needs to be expanded to investigate the role of TGF-β1/2 on Gli1/2 protein
levels and on other Hh mediators such as Ptch1, Ptch2, SMO and Hhip and their
downstream target genes, and how this may contribute to TGF-β2 mediated tumour
growth.

It would also be valuable to examine the role of TGF-β2-induced Gli2 and the
expression of its downstream target genes in MM. Also, the functional effect of
TGF-β2-induced Gli2 on cell proliferation, differentiation, viability, apoptosis,
migration and invasion. This study also needs to be expanded to investigate the
failure of TGF-β1/2 to induce Gli1 using other methods and assays, and subsequently
the functional significance of TGF-β2-mediated effects compared with TGF-β1mediated effects reported by others. To determine if TGF-β2 mediated Gli2 induction
is dependent or independent of Hh signalling, the cyclopamine experiment should be
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further optimised, as well as examining the effect of other Hh signalling inhibitors on
TGF-β2-induced Gli2 for comparison.
Further studies should also investigate the effect of exogenous TGF-β2 on Gli2
expression and the effects of blocking this activation in vivo. A murine model would
provide the opportunity to assess the role of this pathway interaction in vivo tumour
growth. To achieve this, MM cell lines could be transfected with adenoviral vectors
expressing single or combinations of active TGF-β2, SMAD2 or SMAD3 siRNA or
control constructs and transplanted into mice or treated with a Gli inhibitor such as
GANT61 (Mazumdar et al., 2011), and tumour formation compared. The animals
would be killed at various times or once the tumour reached 1 cm in diameter, and
Hh pathway mediators such as Gli1, Gli2, Ptch1, Ptch2, Smo and Hhip levels
measured as well as features such as histopathology, cell proliferation and apoptosis.

Interfering with TGF-β2 signalling has shown promising results in preventing tumour
growth in a variety of tumour types including MM. Similarly, the effect of combined
TGF-β and Gli inhibitors need to be investigated in vitro and in vivo in MM to define
effective therapeutic strategies.
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